

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectables: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Stargemza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tocilizumab-asag) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroyema® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

NSAIDS	
Preferred	Non-Preferred
celecoxib capsule (generic for Celebrex®)	Arthrotec® Tablet
diclofenac sodium tablet (generic for Voltaren®)	Celebrex® Capsule
ibuprofen suspension / tablet (generic for Motrin®)	Daypro® Caplet
indomethacin capsule (generic for Indocin®)	diclofenac potassium capsule (generic for Zipsor®)
ketorolac tablet (generic for Toradol®)	diclofenac potassium tablet (generic for Cataflam®)
meloxicam tablet (generic for Mobic®)	diclofenac sodium ER tablet (generic for Voltaren® XR)
naproxen EC / DR tablet (generic for Naprosyn® EC)	diclofenac sodium-misoprostol tablet (generic for Arthrotec®)
naproxen sodium tablet (generic for Anaprox®)	diflunisal (generic for Dolobid®)
naproxen tablet (generic for Naprosyn®)	Dolobid tablet
sulindac tablet (generic for Clinoril®)	etodolac capsule / tablet / ER tablet (generic for Lodine® / XL)
	Feldene® Capsule
	fenoprofen capsule/ tablet (generic for Nalfon®)
	flurbiprofen tablet (generic for Ansaid®)
	ibuprofen / famotidine tablet (generic for Duexis®) - T/F of only celecoxib required
	indomethacin ER capsule (generic for Indocin SR®)
	indomethacin suppository
	ketoprofen capsule (generic for Orudis®)
	ketoprofen ER capsule (generic for Oruvail®)
	Kiprofen™ (ketoprofen) Capsule (branded generic for Orudis®)
	Lofera™ Tablet
	Lurbiro™ Tablet
	meclfenamate capsule (generic for Meclomen®)
	mefenamic acid capsule (generic for Ponstel®)
	meloxicam capsule (generic for Vivlodex®)
	nabumetone tablet (generic for Relafen®)
	Nalfon® Capsule / Tablet
	Naprelan® Tablet
	Naprosyn® Suspension
	naproxen sodium ER tablet (generic for Naprelan®)
	naproxen suspension (generic for Naprosyn®)
	naproxen-esomeprazole tablet (generic for Vimovo®) - T/F of only celecoxib required
	oxaprozin tablet (generic for DayPro®)
	piroxicam capsule (generic for Feldene®)
	Relafen™ DS Tablet
	Tolectin® (tolmetin) Tablet
	tolmetin tablet / capsule (generic for Tolectin® / DS)
	Vimovo® Tablet - T/F of only celecoxib required
NEUROPATHIC PAIN	
Preferred	Non-Preferred
duloxetine capsule (generic for Cymbalta®)	Cymbalta® Capsule
gabapentin capsule / solution / tablet (generic for Neurontin®)	DermacinRx™ Lidocan Patch - Clinical criteria apply
lidocaine patch (generic for Lidoderm®) - Clinical criteria apply	Drizalma™ Sprinkle
pregabalin capsule /solution (generic for Lyrica®)	duloxetine capsule (generic for Irenka®)
	gabapentin ER tablet (generic for Gralise®)
	Gabarone™ Tablet
	Gralise® Tablet
	Horizant® Tablet
	Lidocan® Patch - Clinical criteria apply
	Lidoderm® Patch - Clinical criteria apply
	Lyrica® Capsule / Solution / CR Tablet
	Neurontin® Capsule / Solution / Tablet
	pregabalin ER tablet (generic for Lyrica® CR)
	Quenza® Kit
	Savella™ Tablet / Titration Pack
	Tridacame™ Patch
	ZTLido™ Patch - Clinical criteria apply
ANTICONVULSANTS	
CARBAMAZEPINE DERIVATIVES	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any carbamazepine product.	
Preferred	Non-Preferred
carbamazepine tablet / suspension / chewable tablet / XR tablet (generic for Tegretol® / XR)	Aptiom® Tablet
Equetrol® Capsule	carbamazepine ER capsule (generic for Carbatrol®)
eslicarbazepine acetate Tablet (generic for Aptiom®)	Carbatrol® Capsule
oxcarbazepine suspension / tablet (generic for Trileptal®)	Epitol® Tablet
Oxtellar® XR Tablet	Oxcarbazepine ER (generic for Oxtellar® XR)
Tegretol® Suspension / Tablet / XR Tablet	Trileptal® Tablet
Trileptal® Suspension	
FIRST GENERATION	
Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any first generation product.	
Preferred	Non-Preferred
Celontin® Kapsceal	Depakote® ER Tablet / Sprinkle Capsule
Dilantin® Capsule / Infatab / Suspension	Depakote® Tablet
divalproex sprinkle capsule / ER tablet / tablet (generic for Depakote® / ER / Sprinkle)	felbamate tablet (generic for Felbatol®)
ethosuximide capsule / solution (generic for Zarontin®)	methsuximide capsule (generic for Celontin®)
felbamate suspension (generic for Felbatol®)	Sezaby® Vial
Felbatol® Suspension / Tablet	Zarontin® Capsule / Solution
phenobarbital tablet / elixir / solution	
Phenytek® Capsule	
phenytoin chewable / extended capsules / infatab / suspension (generic for Dilantin®)	
phenytoin extended capsules (generic for Phenytek®)	
primidone Tablet (generic for Mysoline®)	
valproic acid capsule / solution (generic for Depakene®)	

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® SensorReady® Pen / UnReady® Pen / Syringe, Stegyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellont), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.ncdrugs.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

SECOND GENERATION

Plans may not apply additional utilization management or prior authorization criteria to this category

Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any second generation product.

Preferred	Non-Preferred
Briivact® Tablet / Solution	Banzel® Suspension
clobazam suspension / tablet (generic for Onfi®)	Banzel® Tablet
clonazepam tablet (generic for Klonopin®)	clonazepam ODT (generic for Klonopin® Wafer)
Diacomit® Capsule / Powder Pack	Elepsia™ XR Tablet
diazepam rectal / system (generic for Diastat® Accudial / Pedi System)	Epidiolex® Solution - Clinical criteria apply
Eprontia™ Solution	Gabarone™ Tablet
Fintepla® Solution	Keppra® Tablet / Solution / XR Tablet
Fycompa® Tablet / Suspension	Klonopin® Tablet
gabapentin capsule / solution / tablet (generic for Neurontin®)	lacosamide solution (generic for Vimpat®)
lacosamide tablet (generic for Vimpat®)	Lamictal® Chewable / ODT / ODT Starter Kit / Starter Kit / Tablet / XR / XR Starter Kit
lamotrigine chewable / tablet / ODT (generic for Lamictal®)	lamotrigine ODT dose pack/ tablet dose pack (generic for Lamictal®)
lamotrigine ER tablet (generic for Lamictal® XR)	Levetiracetam tablet (generic for Spritam®)
levetiracetam tablet / ER tablet / solution (generic for Keppra® / XR)	Libervant™ (diazepam) Buccal Film
Nayzilam® Nasal Spray	Lyrica® Capsule / Solution
Qudexy® XR Capsule	Motopoly XR™ (lacosamide extended release) Capsule
Rowcepra™ Tablet	Neurontin® Capsule / Solution / Tablet
rufinamide suspension (generic for Banzel®)	Onfi® Suspension / Tablet
rufinamide tablet (generic for Banzel®)	perampanel Tablet (generic for Fycompa®)
Sabril® Tablet / Powder Packet	Spritam™ Tablet
Subvenite® Tablet / Tab Start Kit	Sympazan® Film
tiagabine tablet (generic for Gabitril®)	Topamax® Sprinkle Capsule / Tablet
topiramate sprinkle capsule / tablet (generic for Topamax®)	topiramate ER capsule (generic for Trokendi XR®) - T/F of Trokendi® XR Capsule required for coverage
Valtoco® Nasal Spray	topiramate ER sprinkle capsule (generic for Qudexy®)
vigabatrin powder packet (generic for Sabril®)	Topiramate Solution
Xcopri® Tablet / Titration Pack	Trokendi® XR Capsule
zonisamide capsule (generic for Zonegran®)	vigabatrin tablet (generic for Sabril®)
	Vigadrone® Powder Packet / Tablet
	Vigafyde™ Solution
	Vigpode™ Powder Packet
	Vimpat® Solution / Starter Kit / Tablet
	Zonisade™ Oral Suspension
	Ztalmly™ Oral Suspension

ANTI-INFECTIVES - SYSTEMIC

ANTIBIOTICS

Penicillins, Cephalosporins and Related

Preferred	Non-Preferred
amoxicillin capsule / chewable / suspension / tablet (generic for Amoxil®, Trimox™)	amoxicillin-clavulanate chewable tablet (generic for Augmentin®)
amoxicillin-clavulanate suspension / tablet (generic for Augmentin®)	amoxicillin-clavulanate XR tablet (generic for Augmentin® / XR)
ampicillin capsule / injection / vial	Augmentin® Suspension / ES-600 / XR Tablet
ampicillin-sulbactam injection / vial	cefalor capsule / suspension / ER tablet (generic for Ceclor® / CD)
Bicillin® C-R injection	cefadroxil tablet (generic for Duricef®)
cefadroxil capsule / suspension (generic for Duricef®)	cefixime suspension (generic for Suprax®) T/F of preferred agents not required for children < 12 years of age
cefdinir capsule / suspension (generic for Omnicef®)	cefepodoxime suspension / tablet (generic for Vantin®)
cefixime capsule (generic for Suprax®)	cephalexin tablet (generic for Keflex®)
cefprozil suspension / tablet (generic for Ceftzil®)	
cefuroxime tablet (generic for Cefin®)	
cephalexin capsule / suspension (generic for Keflex®)	
dicloxacillin capsule	
nafcillin injection / vial	
oxacillin injection / vial	
penicillin G injection / vial	
penicillin V suspension / tablet	
Pfizerpen® injection / vial	
piperacillin - tazobactam injection / vial	
Unasyn® injection / vial	
Zosyn® injection / vial	

Lincosamides and Oxazolidinones

Preferred	Non-Preferred
clindamycin capsules / solution (generic for Cleocin®)	Cleocin® Capsules / Vial
linezolid suspension (oral) / tablet (generic for Zyvox®)	Cleocin® Pediatric Solution
	clindamycin injection (generic for Cleocin®)
	Lincocin® Vial
	lincomycin vial (generic for Lincocin®)
	linezolid IV solution (generic for Zyvox®)
	Sivextro® Tablet / Vial
	Zyvox® Tablet / IV Solution / Suspension

Macrolides and Ketolides

Preferred	Non-Preferred
azithromycin powder packet / suspension / tablet (generic for Zithromax®)	clarithromycin ER tablet (generic for Biaxin XL®)
clarithromycin suspension / tablet (generic for Biaxin®)	Eryped® 200/400 Suspension
E.E.S.® Filmtab / Suspension	Ery-Tab® Tablet
Erythrocin® Filmtab	Zithromax® Powder Packet / Suspension / Tablet / Tri-Pak / Z-Pak
erythromycin ES 200 mg and 400 mg suspension (generic for E.E.S.® Suspension, Eryped®)	
erythromycin EC capsule (generic for Erye®)	
erythromycin filmtab	
erythromycin ES tablet (generic for E.E.S.® Filmtab)	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectable; Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tocilizumab-sarg) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroyvna® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® (Crohn's Starter Pack / Ped, Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs/prescription-drugs/outpatient-pharmacy-services>

Nitroimidazoles (Gastrointestinal Antibiotics)	
Preferred	Non-Preferred
metronidazole tablet (generic for Flagyl®)	Aemcolo® DR Tablet
vancomycin capsule (generic for Vancocin®)	Difcid® Suspension / Tablet - T/F of only vancomycin is required for treatment of Clostridium difficile
vancomycin oral solution (generic for Firvanq®)	Fidaxomicin Tablet (generic for Difcid®)- T/F of only vancomycin is required for treatment of Clostridium difficile
	Firvanq® Solution
	Flagyl® Capsule
	Likmez® Suspension
	metronidazole 125 mg tablet (generic for Flagyl®)
	metronidazole capsule (generic for Flagyl®)
	neomycin tablet (generic for Mycifradin®)
	niiazoxanide tablet (generic for Alinia® Tablet)
	Solosec™ Granules
	tinidazole tablet (generic for Tindamax®)
	Vancocin® Capsule
	Vovst™ Capsule - Clinical criteria apply
Quinolones	
Preferred	Non-Preferred
Cipro® Suspension	Baxdela™ Tablet
ciprofloxacin tablet (generic for Cipro®)	Cipro® Tablet
levofloxacin tablet (generic for Levaquin®)	ciprofloxacin suspension (generic for Cipro®)
moxifloxacin tablet (generic for Avelox®)	levofloxacin solution (generic for Levaquin®)
	ofloxacin tablet (generic for Floxin®)
Tetracycline Derivatives	
Preferred	Non-Preferred
doxycycline hyclate capsule / tablet (generic for Vibramycin®, Vibra-Tab®)	demeclocycline tablet (generic for Declomycin®)
doxycycline monohydrate 50mg, 100mg capsule (generic for Monodox®)	Doryx® DR / MPC Tablet
minocycline 50mg, 75mg, 100mg capsule (generic for Minocin®)	doxycycline hyclate DR tablet (generic for Doryx® DR)
	doxycycline monohydrate 40mg IR-DR capsule (generic for Oracea®)
	doxycycline monohydrate 50mg, 75mg, 100mg, 150mg tablet
	doxycycline monohydrate 75mg, 150mg capsule (generic for Monodox®, Adoxa®)
	doxycycline suspension (generic for Vibramycin®) - T/F of preferred agents not required for patients < 12 years of age
	Lymepak™ Tablet
	minocycline 50mg, 75mg, 100mg tablet
	minocycline ER tablet (generic for Solodyn® ER) Clinical justification and failure of doxycycline and minocycline required. Limited to a 12 week supply.
	Morgidox® Capsule / Kit
	Nuzyn™ Tablet
	Oracea® capsule
	tetracycline capsule (generic for Sumycin®)
	tetracycline tablet (generic for Sumycin® / Panmycin®)
Antifungals	
Preferred	Non-Preferred
clotrimazole troche / lozenge (generic for Mycelex® Troche)	Brexafemme® Tablet
fluconazole suspension / tablet (generic for Diflucan®)	Cresemba® Capsule
griseofulvin suspension (generic for Grifulvin V®)	Diflucan® Suspension / Tablet
griseofulvin ultra tablet (generic for Gris-Peg®)	flucytosine capsule (generic for Ancobon®)
nystatin suspension (generic for Nilstat®)	griseofulvin micro tablets (generic for Grifulvin V®)
nystatin tablet (generic for Mycostatin®)	itraconazole capsule / solution (generic for Sporanox®)
terbinafine tablet (generic for Lamisil®)	ketoconazole tablet (generic for Nizoral®)
	Noxafil® Suspension / Tablet / DR Suspension Packet
	Oravig® Buccal Tablet
	posaconazole tablet / suspension (generic for Noxafil®)
	Sporanox® Capsule / Solution
	Tolsura™ Capsule
	Vfend® Suspension / Tablet
	Vivjoa® Capsule - Clinical criteria apply
	voriconazole suspension / tablet (generic for Vfend®)
Antivirals (General)	
	Plans may not apply additional utilization management or prior authorization criteria to this category
Preferred	Non-Preferred
Paxlovid™ Tablet dose Pack	
Lagevrio™ Capsule	
Antivirals (Hepatitis B Agents)	
Preferred	Non-Preferred
entecavir tablet (generic for Baraclude®)	adefovir tablet (generic for Hepsera®)
lamivudine HBV tablet (generic for Epivir® HBV)	Baraclude® Solution / Tablet
tenofovir disoproxil fumarate tablet (generic for Viread®)	Venlidy® Tablet
Viread® Powder / Tablet	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill FlexPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (teflunomab-asag) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroyem® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Antivirals (Hepatitis C Agents)

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred **Non-Preferred**

Pegasys® Syringe / Vial
ribavirin capsule / tablet (generic for Copegus®, Rebetol®)

Clinical criteria apply to all drugs listed below

Prior Approval Not Required for Mavyret® Tablet / Pellet Pack and sofosbuvir-velpatasvir tablet (generic for Epclusa®)

All genotypes without cirrhosis

Mavyret® Tablet (8 weeks of therapy)
Mavyret® Pellet Pack
sofosbuvir-velpatasvir tablet (generic for Epclusa®)

Epclusa® Pellet Pack/Tablet
Harvoni® Pellet Pack / Tablet
ledipasvir-sofosbuvir tablet (generic for Harvoni®)
Sovaldil® Pellet Pack / Tablet
Zepatier® Tablet

All genotypes with compensated cirrhosis (Child Pugh-A)

Mavyret® Tablet (Up to 12 weeks of therapy)
Mavyret® Pellet Pack
sofosbuvir-velpatasvir tablet (generic for Epclusa®)

All genotypes previously treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.

Vosevi™ Tablet

All genotypes with decompensated cirrhosis

sofosbuvir-velpatasvir tablet (generic for Epclusa®)

Antivirals (Herpes Treatments)

Preferred **Non-Preferred**

acyclovir capsule / tablet / suspension (generic for Zovirax®)
famciclovir tablet (generic for Famvir®)
valacyclovir tablet (generic for Valtrex®)

Valtrex® Caplet

Antivirals (Influenza)

Preferred **Non-Preferred**

oseltamivir phosphate capsule / suspension (generic for Tamiflu®)
rimantadine tablet (generic for Flumadine®)

amantadine tablet (generic for Symmetrel®)
Flumadine™ Tablet
Relenza® Diskhaler
Tamiflu® Capsule / Suspension
Xofluza™ Tablet - T/F of only one preferred drug required

Antibiotics, Inhaled

Plans may not apply additional utilization management or prior authorization criteria to this category

T/F of only one preferred drug required

Preferred **Non-Preferred**

Kitabis™ Pak
Bethkis® Ampule
tobramycin inhalation solution (generic for Tobin™)

Arikayce® Vial
Cayston® Solution
tobramycin inhalation pak (generic for Kitabis™)
Tobi™ Podhaler™ / Solution
tobramycin Ampule (generic for Bethkis)

BEHAVIORAL HEALTH

ANTIDEPRESSANTS

Other

Preferred **Non-Preferred**

bupropion tablet / SR tablet / XL tablet (generic for Wellbutrin® Tablet / SR / XL)
desvenlafaxine ER tablet (generic for Pristiq®)
duloxetine capsule (generic for Cymbalta®)
Effexor® XR Capsule
mirtazapine ODT / tablet (generic for Remeron®)
trazodone tablet (generic for Desyre®)
venlafaxine tablet / ER capsules (generic for Effexor®, Effexor® XR)
vilazodone tablet (generic for Viibryd®)

Auvelity® Tablet
Bupropion XL tablet (generic for Forfivo® XL)
Cymbalta® Capsule
desvenlafaxine ER tablet (generic for Khedezla®)
duloxetine capsule (generic for Irenka®)
Emsam® Patch
Exxun™ ER Tablet / ER Titration Pack
Fetzima® Capsule / Titration Pak
Forfivo® XL Tablet
Marplan® Tablet
Nardil® Tablet
nefazodone tablet (generic for Serzone®)
phenelzine tablet (generic for Nardil®)
Pristiq® ER Tablet
Raldess™ Solution
Remeron® Soltab™ / Tablet
tranylcypromine tablet (generic for Parnate®)
Trintellix® Tablet
venlafaxine besylate ER tablet
venlafaxine ER tablet
Viibryd® Tablet
Wellbutrin® SR

Selective Serotonin Reuptake Inhibitor (SSRI)

Preferred **Non-Preferred**

citalopram solution / tablet (generic for Celexa®)
escitalopram tablet (generic for Lexapro®)
fluoxetine capsule / solution (generic for Prozac®)
fluvoxamine tablet (generic for Luvox®)
paroxetine tablet (generic for Paxil®)
Paxil® Suspension
sertraline concentrated solution / tablet (generic for Zoloft®)

Celexa® Tablet
citalopram capsule
escitalopram solution / Capsule (generic for Lexapro®)
fluoxetine DR capsules (generic for Prozac® Weekly)
fluoxetine tablet (generic for Prozac®) - T/F of preferred agents not required for children < 18 years of age
fluvoxamine ER capsule (generic for Luvox CR®)
Lexapro® Tablet
paroxetine capsule (generic for Brisdelle®)
paroxetine suspension / CR tablet (generic for Paxil® / CR)
Paxil® Tablet / CR Tablet
Prozac® Pulvule
sertraline capsule
Zoloft® Solution / Tablet

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Starjamza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (teclistamab-aszg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Steqyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.ncdrugs.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

ANTIHYPERKINESIS / ADHD

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Adderall® Tablet (Generic Product Per FDA)	Adzenys® XR ODT
Adderall® XR Capsule	Amphetamine ER ODT (generic for Adzenys® XR ODT)- T/F of preferred agents not required for children < 12 years of age
amphetamine salt combo tablet (generic for Adderall®)	amphetamine salt combo ER capsule (generic for Mydavis®)
amphetamine salt combo XR capsule (generic for Adderall® XR)	amphetamine sulfate tablet (generic for Evekeo®)
atomoxetine capsule (generic for Strattera®)	Aptensio® XR Capsule
clonidine ER tablet (generic for Kapvay®)	Azstarys® Capsule
Concerta® Tablet	Cotempla™ XR-ODT
Daytrana® Patch	Dexedrine® Spansule®
dexamethylphenidate tablet / ER capsule (generic for Focalin® / XR)	dextroamphetamine ER capsule (generic for Dexedrine® Spansule®)
dextroamphetamine tablet (generic for Dexedrine®)	dextroamphetamine solution (generic for ProCentra®)
guanfacine ER tablet (generic for Intuniv®)	Dvanavel® XR Suspension - T/F of preferred agents not required for children < 12 years of age
lisdexamfetamine chewable tablet (generic for Vyvanse®)	Dvanavel® XR Tablet
Methylin® Solution	Evekeo® Tablet / Evekeo® ODT Tablet
methylphenidate CD capsule (generic for Metadate® CD)	Focalin® Tablet
methylphenidate ER tablet (generic for Concerta®)	Focalin® XR Capsule
methylphenidate tablet / solution (generic for Methylin®, Ritalin®)	Intuniv® Tablet
Vyvanse® Capsule	Jomav PM™ Capsule
Vyvanse® Chewable Tablet	lisdexamfetamine capsule (generic for Vyvanse®)
	methamphetamine tablet (generic for Desoxyn®)
	methylphenidate chewable (generic for Methylin®)
	methylphenidate ER capsule (generic for Aptensio® XR)
	methylphenidate ER tablet (45 mg and 63 mg) (Branded Product Per FDA)
	methylphenidate LA capsule (generic for Ritalin® LA)
	methylphenidate patch (generic for Daytrana®)
	Mydavis® ER Capsule
	Onyda XR Suspension- T/F of preferred agents not required for children < 12 years of age
	ProCentra® Solution
	Qelbree® Capsule
	Quilichew® ER Tablet - T/F of preferred agents not required for children < 12 years of age
	Quillivant® XR Suspension - T/F of preferred agents not required for children < 12 years of age
	Relexxi™ ER Tablet
	Ritalin® LA Capsule
	Ritalin® Tablet
	Strattera® Capsule
	Xelstrym® Patch
	Zenzedi® Tablet

INJECTABLE ANTIPSYCHOTICS

Injectable Long Acting

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Abilify Asimtufi® Syringe Kit	
Abilify Maintena® Syringe / Vial	
Aristada® / Initio™ Syringe	
Erzofri® (paliperidone palmitate) extended-release injectable suspension	
fluphenazine decanoate vial (generic for Prolixin decanoate™)	
Haldol® decanoate Ampule	
haloperidol decanoate ampule / vial (generic for Haldol decanoate™)	
Invega® Hafvera Prefilled Syringe Kit	
Invega® Sustenna Prefilled Syringe	
Invega® Trinza Syringe	
Perseris® Syringe	
Risperdal® Consta Vial	
risperidone ER vial (generic for Risperdal® Consta)	
Rykindo® Vial / Vial Kit	
Uzedy™ Syringe Kit	
Zyprexa® Relprevv™ Vial Kit	

ATYPICAL ANTIPSYCHOTICS

Oral / Transdermal

Plans may not apply additional utilization management or prior authorization criteria to this category

T/F of only one preferred drug required

Preferred	Non-Preferred
aripiprazole Tablet / Solution (generic for Abilify®)	Abilify® Tablet / Abilify® MyCite® Tablet
asenapine SL tablet (generic for Saphris® SL)	aripiprazole ODT (generic for Abilify® Disemelt®)
clozapine tablet (generic for Clozaril®)	Caplyta™ Capsule
lurasidone tablet (generic for Latuda®)	clozapine ODT (generic for FazaClo®)
olanzapine ODT / tablet (generic for Zyprexa®)	Clozaril® Tablet
paliperidone ER tablet (generic for Invega®)	Cobenly
quetiapine tablet / ER tablet (generic for Seroquel® / XR)	Cobenly Starter Pack
risperidone ODT / solution / tablet (generic for Risperdal®)	Fanapt® Tablet / Titration Pack
Vraylar® Capsule	Geodon® Capsule
ziprasidone capsule (generic for Geodon®)	Invega® Tablet
	Latuda® Tablet
	Lybalvi™ Tablet
	Nuplazid® Tablet / Capsule
	olanzapine-fluoxetine capsule (generic for Symbyax®)
	Opipza™ (Aripiprazole) Oral Film
	Rexulti® Tablet / 7-Day Pack / 14-Day Pack
	Risperdal® Solution / Tablet
	Saphris® SL Tablet
	Secuado® Patch
	Seroquel® Tablet / XR Tablet / XR Sample Kit
	Versacloz® Suspension
	Zyprexa® Tablet / Zydys® Tablet

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill FlexPen® Vial to preferred status in the Hypoglycemic-Injectables: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-sarg) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Steqyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® (Crohn's Starter Pack / Ped, Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

CARDIOVASCULAR

ACE INHIBITORS

Preferred	Non-Preferred
benazepril tablet (generic for Lotensin®)	Accupril® Tablet
enalapril tablet (generic for Vasotec®)	Altace® Capsule
lisinopril tablet (generic for Prinivil® and Zestril®)	captopril tablet (generic for Capoten®)
ramipril capsule (generic for Altace®)	enalapril solution (generic for Epaned®) - T/F of preferred agents not required for children < 12 years of age
	Epaned® Solution - T/F of preferred agents not required for children < 12 years of age
	fosinopril tablet (generic for Monopril®)
	Lotensin® Tablet
	moexipril tablet (generic for Univas®)
	perindopril tablet (generic for Aceon®)
	Qbrelis® Solution - T/F of preferred agents not required for children < 12 years of age
	quinapril tablet (generic for Accupril®)
	trandolapril tablet (generic for Mavik®)
	Zestril® Tablet

ACE INHIBITOR / CALCIUM CHANNEL BLOCKER COMBINATIONS

Preferred	Non-Preferred
amlodipine-benazepril capsule (generic for Lotrel®)	Lotrel® Capsule
	trandolapril-verapamil ER tablet (generic for Tarka®)

ACE INHIBITOR / DIURETIC COMBINATIONS

Preferred	Non-Preferred
enalapril-HCTZ tablet (generic for Vasercet®)	Accuretic® Tablet
lisinopril-HCTZ tablet (generic for Prinzide®, Zestoretic®)	benazepril-HCTZ tablet (generic for Lotensin® HCT)
	captopril-HCTZ tablet (generic for Capozide®)
	fosinopril-HCTZ tablet (generic for Monopril® HCT)
	Lotensin® HCT Tablet
	quinapril-HCTZ tablet (generic for Accuretic®, Quinaretic®)
	Vaseretic® Tablet
	Zestoretic® Tablet

ANGIOTENSIN II RECEPTOR BLOCKERS

Preferred	Non-Preferred
irbesartan tablet (generic for Avapro®)	Arbim® Suspension
losartan tablet (generic for Cozaar®)	Atacand® Tablet
olmesartan tablet (generic for Benicar®)	Avapro® Tablet
valsartan tablet (generic for Diovan®)	Benicar® Tablet
	candesartan tablet (generic for Atacand®)
	Cozaar® Tablet
	Diovan® Tablet
	Edarbi® Tablet
	eprosartan tablet (generic for Teveten®)
	Micardis® Tablet
	telmisartan tablet (generic for Micardis®)
	valsartan oral solution

ANGIOTENSIN II RECEPTOR BLOCKER COMBINATIONS

Preferred	Non-Preferred
amlodipine-olmesartan tablet (generic for Azor®)	Azor® Tablet
amlodipine-valsartan tablet (generic for Exforge®)	Exforge® Tablet / HCT Tablet
olmesartan-amlodipine-HCTZ tablet (generic for Tribenzor®)	telmisartan-amlodipine tablet (generic for Twynsta®)
	Tribenzor® Tablet
	amlodipine-valsartan-HCTZ tablet (generic for Exforge® HCT)

ANGIOTENSIN II RECEPTOR BLOCKER DIURETIC COMBINATIONS

Preferred	Non-Preferred
irbesartan-HCTZ tablet (generic for Avalide®)	Atacand® HCT Tablet
losartan-HCTZ tablet (generic for Hyzaar®)	Avalide® Tablet
olmesartan-HCTZ tablet (generic for Benicar® HCT)	Benicar® HCT Tablet
valsartan-HCTZ tablet (generic for Diovan® HCT)	candesartan-HCTZ tablet (generic for Atacand® HCT)
	Diovan® HCT Tablet
	Edarbyclor® Tablet
	Hyzaar® Tablet
	Micardis® HCT Tablet
	telmisartan-HCTZ tablet (generic for Micardis® HCT)

ANGIOTENSIN II RECEPTOR / NEPRILYSIN BLOCKER COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Entresto® Tablet	Entresto® (sacubitril / valsartan) Sprinkle Pellet- T/F of preferred agents not required for children < 12 years of age
	sacubitril and valsartan tablet (generic for Entresto®)

ANTIANGINAL & ANTI-ISCHEMIC

Preferred	Non-Preferred
ranolazine ER tablet (generic for Ranexa® Tablet)	Aspruvo™ Sprinkle

ANTI-ARRHYTHMICS

Preferred	Non-Preferred
amiodarone tablet (generic for Cordarone®)	Multaq® Tablet
disopyramide capsule (generic for Norpace®)	Norpace® Capsule / CR Capsule
dofetilide capsule (generic for Tikosyn®)	Pacerone® Tablet
flecainide tablet (generic for Tambocor®)	quinidine gluconate ER tablet (generic for Quinaglute DuraTabs®)
mexiletine capsule (generic for Mexitil®)	Tikosyn® Capsule
propafenone tablet (generic for Rythmol®)	
propafenone SR capsule (generic for Rythmol SR®)	
quinidine sulfate tablet (generic for Quinidex® Tablet)	

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starganza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroyem® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Qualitest), and Humira® (Crohn's Starter Pack / Pen, Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglyss™ (lebrkizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

BETA BLOCKERS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
atenolol tablet (generic for Tenormin®)	acebutolol capsule (generic for Sectral®)
bisoprolol tablet (generic for Zebeta®)	Betapace® Tablet / AF Tablet
carvedilol tablet (generic for Coreg®)	betaxolol tablet (generic for Kerlone®)
Hemangeol® Solution	Bystolic® Tablet
labetalol tablet (generic for Trandate®)	carvedilol ER capsule (generic for Coreg® CR Capsule)
metoprolol succinate XL tablet (generic for Toprol XL®)	Coreg® Tablet / CR Capsule
metoprolol tartrate tablet (generic for Lopressor®)	Inderal® LA Capsule / XL Capsule
nadolol tablet (generic for Corgard®)	Innopran® XL Capsule
nebivolol tablet (generic for Bystolic®)	Kapsargo® Sprinkle - T/F of preferred agents not required for children < 12 years of age
propranolol solution / tablet / ER capsule (generic for Inderal®)	Lopressor® Tablet / Solution
sotalol tablet / AF tablet (generic for Betapace® / AF, Sorine®)	pindolol tablet (generic for Visken®)
	Sotylize® Solution
	Tenormin® Tablet
	timolol tablet (generic for Blocadren®)
	Toprol XL® Tablet

BETA BLOCKER DIURETIC COMBINATIONS

Preferred	Non-Preferred
atenolol-chlorthalidone tablet (generic for Tenoretic®)	metoprolol-HCTZ tablet (generic for Lopressor® HCT)
bisoprolol-HCTZ tablet (generic for Ziac®)	propranolol-HCTZ tablet (generic for Inderide®)
	Tenoretic® Tablet

BILE ACID SEQUESTRANTS

Preferred	Non-Preferred
cholestyramine packet / powder / light packet / light powder (generic for Questran® / Questran® Light)	colesevelam packet / tablet (generic for Welchol®)
colestipol tablet (generic for Colestid® Tablet)	Colestid® Granules / Tablet
	colestipol granules (generic for Colestid®)
	Prevalite® Packet / Powder
	Questran® Light Powder / Packet / Powder
	Welchol® Packet / Tablet

CARDIOVASCULAR, OTHER

Preferred	Non-Preferred
Canzyos® Capsule - Clinical criteria apply	Lodoco®

CHOLESTEROL LOWERING AGENTS

Preferred	Non-Preferred
atorvastatin tablet (generic for Lipitor®)	Altoprev® Tablet
ezetimibe (generic for Zetia®)	amlodipine-atorvastatin tablet (generic for Caduet®)
lovastatin tablet (generic for Mevacor®)	Atorvaliq® Suspension
pravastatin tablet (generic for Pravachol®)	Caduet® Tablet
rosuvastatin tablet (generic for Crestor®)	Crestor®
simvastatin tablet (generic for Zocor®)	Ezallor™ Capsule
	ezetimibe-simvastatin (generic for Vytorin®)
	fluvastatin capsule / ER tablet (generic for Lescol® / XL)
	Juxtapid® Capsule - Clinical criteria apply
	Lescol® XL Tablet
	Lipitor® Tablet
	Livalo® Tablet - T/F of preferred agents not required with concomitant antiretroviral therapy in patients diagnosed with HIV
	Nexletol® Tablet - Clinical criteria apply
	Nexlizet® Tablet - Clinical criteria apply
	pitavastatin tablet (generic for Livalo®) - T/F of preferred agents not required with concomitant antiretroviral therapy in patients diagnosed with HIV
	Vytorin® Tablet
	Zetia® Tablet
	Zocor® Tablet
	Zypitamag™ Tablet

CORONARY VASODILATORS

Preferred	Non-Preferred
isosorbide dinitrate tablet (generic for Isordil® Titradose®, IsoDitrat®, et al.)	Gonitro® Sublingual Powder
isosorbide mononitrate tablet / ER tablet (generic for Ismo®, Monoket®, Indur®)	Nitro-Bid® Ointment
nitroglycerin patch / spray / SL tablet (generic for Nitro-Dur®, Minitran®, Nitrostat®, et al.)	Nitro-Dur® Patch
Nitrostat® SL Tablet	nitroglycerin ointment (generic for Nitro-Bid®)
	Nitrolinqual® Spray
	Verquvo™ Tablet

DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
amlodipine tablet (generic for Norvasc®)	felodipine ER tablet (generic for Plendil®)
nifedipine capsule (generic for Procardia®)	isradipine capsule (generic for Dynacirc®)
nifedipine ER tablet (generic for Adalat CC® / Procardia XL®)	Katerzia™ Suspension - T/F of preferred agents not required for children < 12 years of age
Norliqua® Solution	levamlodipine tablet (generic for Contiup®)
	nicardipine capsule (generic for Cardene®)
	nimodipine capsule (generic for Nimotop®)
	nimodipine solution
	nisoldipine ER tablet (generic for Sular®)
	Norvasc® Tablet
	Nymalize® Solution / oral syringe
	Procardia® XL Tablet
	Sular® Tablet

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® / Vial to preferred status in the Hypoglycemic-Injectables/ Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (teflunomab-asag) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroycyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.ncdrugs.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

DIRECT RENIN INHIBITOR		
Preferred		Non-Preferred
Tektura® Tablet	alisikren tablet (generic for Tektura® Tablet)	
Tektura® HCT Tablet		
ENDOTHELIN RECEPTOR ANTAGONISTS		
Covered for diagnosis of Pulmonary Arterial Hypertension only		
Preferred		Non-Preferred
ambisentan tablet (generic for Letairis® Tablet)	bosentan tablet /tablet for suspension (generic for Tracleer®)	
Tracleer® Tablet	Letairis® Tablet Opsumit® Tablet Opsumvi® Tablet Tracleer® Suspension	
INHALED PROSTACYCLIN ANALOGS		
Preferred		Non-Preferred
Tyvaso® Refill Kit / Solution / Starter Kit	Tyvaso® DPI	
Ventavis® Solution	Yutrepia™ DPI	
NIACIN DERIVATIVES		
Preferred		Non-Preferred
niacin ER tablet (generic for Niaspan®)		
NITRATE COMBINATION		
Preferred		Non-Preferred
Bidil® Tablet	isosorbide dinit/hydralazine tablet (generic for Bidil®)	
NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS		
Preferred		Non-Preferred
Cartia XT® Capsule (branded generic for Cardizem CD®)	diltiazem LA tablet (generic for Cardizem LA®)	
Dilt XR® Capsule (branded generic for Dilacor XR®)	Matzim® LA Tablet (generic for Cardizem LA®)	
diltiazem ER 24 hour capsule (generic for Dilacor XR®, Tiazac®)	Verapamil Capsule SR (generic for Verelan®)	
diltiazem tablet / CD capsule / ER 12 hour capsule (generic for Cardizem® / CD / SR)	verapamil ER capsule / PM capsule (generic for Verelan® / Verelan® PM)	
Taztia XT® Capsule (branded generic for Tiazac®)	Verelan® PM Capsule	
Tiadvt® ER Capsule		
verapamil tablet / ER tablet (generic for Calan® / SR)		
ORAL PULMONARY HYPERTENSION		
Covered for diagnosis of Pulmonary Arterial Hypertension (all) and Chronic Thromboembolic Pulmonary Hypertension- Adempas® only		
Preferred		Non-Preferred
Alyq® Tablet (branded generic for tadalafil)	Adcirca® Tablet	
sildenafil tablet (generic for Revatio®)	Adempas® Tablet	
tadalafil tablet (generic for Adcirca®)	Orenitram® ER Tablet / Titration Kit Revatio® Suspension / Tablet - T/F of preferred agents not required for children < 12 years of age for Suspension ONLY sildenafil suspension (generic for Revatio®) - T/F of preferred agents not required for children < 12 years of age Tadliq® Suspension Upravi® Tablet / Titration Pack	
PCSK9		
Plans may not apply additional utilization management or prior authorization criteria to this category Clinical criteria apply to all drugs in this class		
Preferred		Non-Preferred
Repatha® Syringe / Pushtronix / Sureclick	Leqvio® Injection	
Praluent® Pen		
PLATELET INHIBITORS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Brilinta® Tablet	aspirin/dipyridamole ER capsule (generic for Aggrenox®)	
clopidogrel tablet (generic for Plavix®)	Effient® Tablet	
dipyridamole tablet (generic for Persantine®)	Plavix® Tablet	
prasugrel tablet (generic for Effient® Tablet)	Ticagrelor Tablet (generic for Brilinta®)	
SYMPATHOLYTICS AND COMBINATIONS		
Preferred		Non-Preferred
clonidine tablet / patch (generic for Catapres® / TTS)	clonidine ER tablet (generic for Nexiclon™ XR)	
guanfacine tablet (generic for Tenex®)	methylodopa-HCTZ tablet (generic for Aldoril®)	
methylodopa tablet (generic for Aldomet®)	methylodopa vial (generic for Aldomet®) Nexiclon™ XR Tablet	
TRIGLYCERIDE LOWERING AGENTS		
Preferred		Non-Preferred
fenofibrate tablet (generic for Tricor®)	fenofibrate capsule / tablet (generic for Antara®, Lofibra®, Fenoglide®, et. al)	
gemfibrozil tablet (generic for Lopid®)	fenofibric acid tablet (generic for Fibricor®, Trilipix®)	
icosapent ethyl capsule (generic for Vascepa®)	Fibricor® Tablet	
omega-3 acid ethyl esters capsule (generic for Lovaza®)	Lipofen® Capsule	
	Lopid® Tablet	
	Tricor® Tablet	
	Trilipix® Capsule	

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® Vial to preferred status in the Hypoglycemic-Injectable/ Rapid acting Insulin category, due to patient access, effective 03.20.2026.

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Stajenza Vial / Syringe (biosimilar to Stelara®), and Tyenac® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Steqyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

CENTRAL NERVOUS SYSTEM

ANTIMIGRAINE AGENTS

Quantity limits apply to all triptans

Preferred	Non-Preferred
rizatriptan tablet / ODT (generic for Maxalt®)	almotriptan tablet (generic for Axert®)
sumatriptan nasal spray / tablet / vial (generic for Imitrex®)	diclofenac potassium powder packet (generic for Cambia®) - T/F of 2 preferred NSAIDs, in addition to T/F of 2 preferred triptans in the Antimigraine Agents class required for coverage
	eletriptan tablet (generic for Relpax®)
	Elyxyb™ Solution - T/F of 2 preferred NSAIDs, in addition to T/F of 2 preferred triptans in the Antimigraine Agents class required for coverage
	Frova® Tablet
	frovatriptan tablet (generic for Frova®)
	Imitrex® Cartridge / Nasal Spray / Pen / Tablet
	Maxalt® Tablet / MLT Tablet
	naratriptan tablet (generic for Amerge®)
	Relpax® Tablet
	Reyvow™ Tablet
	sumatriptan / naproxen tablet (generic for Treximet®)
	sumatriptan injection kit / refill / syringe (generic for Imitrex®)
	Symbravo® Tablet
	Tosymra™ Nasal Spray
	Zembrace® SymTouch®
	zolmitriptan nasal spray / ODT / tablet (generic for Zomig®)
	Zomig® Nasal Spray / Tablet

ANTIMIGRAINE AGENTS

CGRP Blockers/Modulators PREVENTATIVE

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Aimovig® Autoinjector	Emgality® Syringe 100 MG
Ajovy® Autoinjector / Syringe	Vvepti® Vial
Emgality® Pen / Syringe	
Nurtec® ODT	
Qulipta® Tablet	

ANTIMIGRAINE AGENTS

CGRP Blockers/Modulators ACUTE TREATMENT

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Nurtec® ODT	Zavzpret™ Nasal Spray
Ubrovvy® Tablet	

ANTI-NARCOLEPSY

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Provigil® Tablet	armodafinil tablet (generic for Nuvigil®)
	modafinil tablet (generic for Provigil®)
	Nuvigil® Tablet
	Sunosi™ Tablet
	Wakix® Tablet

ANTI-PARKINSON AND RESTLESS LEG SYNDROME AGENTS

Preferred	Non-Preferred
amantadine capsule / solution (generic for Symmetrel®)	Apokyn® Cartridge
benztropine tablet (generic for Cogentin®)	apomorphine cartridge (generic for Apokyn®)
bromocriptine capsule / tablet (generic for Parlodel®)	Azilect® Tablet
carbidopa-levodopa ODT (generic for Parcopa®)	carbidopa tablet (generic for Lodossyn®)
carbidopa-levodopa tablet / ER tablet (generic for Sinemet® / CR)	carbidopa-levodopa-entacapone tablet (generic for Stalevo®)
pramipexole tablet (generic for Mirapex®)	Crexont Capsule ER
ropinirole tablet (generic for Requip®)	Dhivv Tablet™
selegiline capsule / tablet (generic for Emsam®)	Duopa® Suspension
trihexphenidyl elixir / tablet (generic for Artane®)	entacapone tablet (generic for Comtan®)
	Gocovri™ Capsule - Clinical criteria apply
	Horizant® Tablet
	Inbrija™ Inhalation - Clinical criteria apply
	Neupro® Patch
	Nourianz™ Tablet
	Onapgo™ Cartridge
	Ongentys® Capsule- Clinical criteria apply
	Osmolex ER™ Tablet - Clinical criteria apply
	pramipexole ER tablet (generic for Mirapex ER®)
	rasagiline tablet (generic for Azilect®)
	ropinirole ER tablet (generic for Requip XL®)
	Rytary® ER Capsule
	Sinemet® Tablet
	Stalevo® Tablet
	tolcapone tablet (generic for Tasmar®)
	Vyalev Vial
	Xadago® Tablet

MULTIPLE SCLEROSIS

Injectable

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Avonex® Pack / Pen / Syringe	Briumvi™ Vial
Betaseron® Kit / Vial	Copaxone® 40 MG/ML Syringe
Copaxone® Syringe 20 MG/ML	glatiramer syringe 20 MG/ML (generic for Copaxone® Syringe)
glatiramer syringe 40 MG/ML (generic for Copaxone® Syringe)	Glatapa® Syringe
Kesimpta® Pen	Lemtrada® Vial
Rebif® Rebifdose® / Titration Pack / Syringe	Ocrevus® Vial - T/F of preferred agents not required for diagnosis of Primary Progressive MS (PPMS)
	Ocrevus® Zonovo Vial T/F of preferred agents not required for diagnosis of Primary Progressive MS (PPMS)
	Plegridy® Pen / Pen Starter Pack / Syringe / Syringe Starter Pack
	Tysabri® Vial

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® / Vial to preferred status in the Hypoglycemics-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Starjenzia Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tefimizumab-sazg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stegyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Preferred	Oral	Non-Preferred
dalfampridine ER tablet (generic for Ampyra®)	Ampyra® Tablet	
dimethyl fumarate DR capsule / starter pack (generic for Tecfidera® Capsule / Starter Pack)	Aubagio® Tablet	
fingolimod capsule (generic for Gilenya®)	Bafiertam™ Capsule	
teriflunomide tablet (generic for Aubagio®)	Gilenya® Capsule	
	Mavenclad® Tablet	
	Mayzent® Starter Pack / Tablet	
	Ponvory® Starter Pack / Tablet	
	Tascenso ODT™	
	Tecfidera® Capsule / Starter Pack	
	Vumerity™ Capsule	
	Zeposia® Starter Pack / Capsule	
AMYOTROPHIC LATERAL SCLEROSIS (ALS) AGENTS		
riluzole tablet (generic for Rilutek®)	edaravone infusion bag (generic for Radicava®)	
	edaravone Vial (generic for Radicava®)	
	Qalsody™ Vial T/F of preferred agents not required for SOD1 gene mutation	
	Radicava® ORS® Suspension / ORS® Starter Kit Suspension / Infusion Bag	
	Tiglutik® Suspension	
SEDATIVE HYPNOTICS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Quantity limits apply to all sedative hypnotics		
eszopiclone tablet (generic for Lunesta®)	Ambien® Tablet / CR Tablet	
flurazepam capsule (generic for Dalmane®)	Belsomra® Tablet	
ramelteon tablet (generic for Rozerem® Tablet)	Dayvigo™ Tablet	
temazepam 15mg, 30mg capsule (generic for Restoril®)	Doral® Tablet	
zaleplon capsule (generic for Sonata®)	doxepin tablet (generic for Silenor®)	
zolpidem tablet (generic for Ambien®)	Edluar® SL Tablet	
zolpidem ER tablet (generic for Ambien® CR)	estazolam tablet (generic for Prosom®)	
	Halcion® Tablet	
	Hetlioz® Capsule / LQ Suspension - Clinical criteria apply	
	Lunesta® Tablet	
	quazepam tablet (generic for Doral®)	
	Quviviq™ Tablet	
	Restoril® Capsule	
	Rozerem® Tablet	
	tasimelteon capsule (generic for Hetlioz®) - Clinical criteria apply, T/F of Hetlioz® Capsule required for coverage	
	temazepam 7.5, 22.5 mg capsule (generic for Restoril®)	
	triazolam tablet (generic for Halcion®)	
	zolpidem capsule	
	zolpidem SL tablet (generic for Intermezzo®)	
TOBACCO CESSATION		
bupropion SR tablet (generic for Zyban®)	Nicotrol® Inhaler / NS Nasal Spray	
Chantix® Tablet / Starting Box / Continuation Month Box		
nicotine gum / lozenge (buccal) / patch		
varenicline tablet / starting month box (generic for Chantix®)		
varenicline continuation month box (generic for Chantix®)		
ENDOCRINOLOGY		
GROWTH HORMONE		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Clinical criteria apply to all drugs in this class		
Prior Approval Not Required for Use of Serostim® in AIDS Wasting Syndrome		
Genotropin® Cartridge / MiniQuick®	Humatrope® Cartridge	
Norditropin® Flexpro®	Ngenia® Pen	
Skytrofa® Cartridge	Nutropin® AQ NuSpin®	
	Omnitrope® Cartridge / Vial	
	Serostim® Vial	
	Sogroya® Pen	
	Zomacton® Vial	
HYPOGLYCEMICS - INJECTABLE		
Rapid Acting Insulin		
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.		
insulin aspart U-100 Penfill/ FlexPen® / vial (generic for Novolog®) (generic for Novolog®)	Admelog® SoloStar® / Vial	
insulin lispro U-100 Junior KwikPen® (generic for Humalog® Junior)	Afreza® Inhalation Powder	
insulin lispro U-100 KwikPen® / vial (generic for Humalog®)	Apidra® SoloStar® / Vial	
Novolog® U-100 Penfill/ FlexPen® / Vial	Fiasp® FlexTouch® / Penfill® / PumpCart® / Vial	
Relion Novolog® U-100 FlexPen® / Vial	Humalog® U-100 Cartridge/ Junior KwikPen®/ KwikPen® / Vial	
	Humalog® U-100 Tempo Pen™	
	Humalog® U-200 KwikPen®	
	Kirsty Vial / Pen (biosimilar to Novolog®)	
	Lyumjev™ U-100 KwikPen® / U-200 KwikPen® / Vial	
	Merilog Solostar® Pen	
	Merilog® Vial	
Short Acting Insulin		
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.		
Humulin® R Vial	Myxredlin™ Injection	
Humulin® R U-500 KwikPen® / U500 Vial	Novolin® R Vial / ReliOn® R Vial	
	Novolin R FlexPen® / ReliOn® R FlexPen	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Starganza Vial / Syringe (biosimilar to Stelara®), and Tyenno® (tedizolid-nbsag) Antoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroycyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrizikumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Intermediate Acting Insulin	
Preferred	Non-Preferred
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
Humulin® N Vial	Humulin® N KwikPen® Novolin® N FlexPen® / ReliOn® N FlexPen® Novolin® N Vial / ReliOn® N Vial
Long Acting Insulin	
Plans may not apply additional utilization management or prior authorization criteria to this category	
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
Preferred	Non-Preferred
insulin glargine vial / SoloStar® (authorized biologic for Lantus) Lantus® SoloStar® / Vial	Basaglar® U-100 KwikPen® Basaglar® U-100 Tempo Pen™ insulin degludec pen / vial (generic for Tresiba®) insulin glargine SoloStar® / Max SoloStar® (generic for Toujeo®) insulin glargine-yfjn pen / vial (generic for Semglee™ yfjn) Levemir® / FlexPen® / FlexTouch® / Vial Rezvoglar™ Kwikpen® Semglee™ yfjn Pen / Vial Toujeo® SoloStar® / Max SoloStar® Tresiba® FlexTouch® / Vial
Premixed Rapid Combination Insulin	
Preferred	Non-Preferred
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
insulin lispro protamine 75/25 KwikPen® (generic for Humalog® 75/25 Mix)	Humalog® 75/25 Mix KwikPen® Humalog® 50/50 Mix KwikPen® Humalog® 75/25 Vial
Premixed 70/30 Combination Insulin	
Preferred	Non-Preferred
T/F of only one preferred drug required; Prior authorization is required for NP insulins. Prior authorizations may be valid for up to 3 years for beneficiaries with Type 1 Diabetes.	
insulin aspart protamine-aspart 70/30 U-100 FlexPen® (generic for Novolog® Mix 70/30) Humulin® 70/30 KwikPen® / Vial	Novolin® 70/30 FlexPen® / Vial Novolog® Mix 70/30 Vial / FlexPen® Relion Novolin® (human insulin NPH / human insulin) 70/30 FlexPen® Relion Novolin® 70/30 Vial Relion Novolog® 70/30 Vial / FlexPen®
Amylin Analogs	
Requires T/F or insufficient response to metformin containing product unless contraindicated or documented adverse event when using either a preferred or non-preferred Amylin Analog	
Preferred	Non-Preferred
Symlin® Pen Injector	
GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Clinical criteria apply to all drugs in this class	
Preferred	Non-Preferred
Byetta® Pen Trulicity® Pen Victoza® Pen Ozempic® Pen	Bydureon® BCise™ exenatide Pen (generic for Byetta®) liraglutide pen (generic for Victoza®) Mounjaro™ Pen Rybelsus® Tablet Soliqua® Pen Xultophy® Pen
HYPOGLYCEMICS - ORAL	
2nd Generation Sulfonylureas	
Preferred	Non-Preferred
gliclazide tablet (generic for Amaryl®) gliclazide tablet / ER tablet (generic for Glucotrol® / XL) Glucotrol® XL Tablet glyburide micronized tablet (generic for Micronase®, Glymase®) glyburide tablet (generic for Diabeta®)	
Alpha-Glucosidase Inhibitors	
Preferred	Non-Preferred
acarbose tablet (generic for Precose®)	miglitol tablet (generic for Glyset®) Precose® Tablet
Biguanides and Combinations	
Preferred	Non-Preferred
glipizide-metformin tablet (generic for Metaglip®) glyburide-metformin tablet (generic for Glucovance®) metformin tablet / ER tablet (generic for GlucoPhane® / ER)	metformin ER tablet (generic for Fortamet®) metformin ER tablet (generic for Glumetza®) metformin solution (generic for Riomet®), T/F of preferred agents not required for children < 12 years of age metformin tablet (625 mg) Riomet® Solution

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable/ Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-asag) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Sensesready® Pen / UnoReady® Pen / Syringe, Stroyema® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

BILE ACID SALTS

T/F of only one preferred drug required

Preferred	Non-Preferred
ursodiol capsule (generic for Actigall®)	Bilvay™ Capsule / Pellet - T/F of preferred agents not required for diagnosis of PFIC
ursodiol tablet (generic for Urso®)	Chenodal® Tablet
	Cholbam® Capsule
	Ctexli™ Tablet
	Iqirvo® (elafibranor) Tablet
	Livdelzi Capsule
	Livmarli® Oral Solution/ Tablet
	Ocaliva™ Tablet
	Reltone™ Capsule
	Urso Forte® Tablet

H. PYLORI COMBINATIONS

Preferred	Non-Preferred
Pylera® Capsule	bismuth / metronidazole / tetracycline capsule (generic for Pylera®)
	lansoprazole-amoxicillin-clarithromycin pack (generic for Prevpac®)
	Omeclamox-Pak® Combo Pack
	Talicia™ Capsule
	Voquezna™ Tablet / Dual Pak / Triple Pak

HISTAMINE-2 RECEPTOR ANTAGONISTS

Preferred	Non-Preferred
famotidine tablet / suspension (generic for Pepcid®)	cimetidine tablet (generic for Tagamet®)
	cimetidine solution (generic for Tagamet®)
	nizatidine capsule (generic for Axid®)

PANCREATIC ENZYMES

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Creon® Capsule	Pertzye® Capsule
Viokase® Tablet	
Zenpep® Capsule	

PROGESTINS USED FOR CACHEXIA

Preferred	Non-Preferred
megestrol suspension / tablet (generic for Megace®)	megestrol ES suspension (generic for Megace® ES)

PROTON PUMP INHIBITORS

Preferred	Non-Preferred
-----------	---------------

T/F of preferred agents not required for children < 12 years of age

esomeprazole magnesium capsule (generic for Nexium® Rx)	Dexilant® Capsule
lansoprazole capsule (generic for Prevacid® Rx)	dexlansoprazole capsules (generic for Dexilant®)
Nexium® Rx Packet	esomeprazole magnesium OTC capsule / tablet (generic for Nexium® OTC)
omeprazole Rx capsule (generic for Prilosec® Rx)	esomeprazole magnesium packet (generic for Nexium® Rx Packet)
pantoprazole tablet (generic for Protonix®)	Konvomep™ Suspension
Protonix® Suspension	lansoprazole capsule (generic for Prevacid® OTC)
	lansoprazole ODT (generic for Prevacid® SoluTab™)
	Nexium® Rx Capsule
	omeprazole OTC capsule / ODT / tablet (generic for Prilosec® OTC)
	omeprazole-sodium bicarbonate capsule / packet (generic for Zegerid® Rx / OTC)
	pantoprazole suspension (generic for Protonix®)
	Prevacid® Rx / OTC Capsule / Solutab
	Prilosec® Rx Suspension
	Protonix® Tablet
	rabeprazole tablet (generic for Aciphex®)

SELECTIVE CONSTIPATION AGENTS

Preferred	Non-Preferred
Linzess® Capsule	alosetron tablet (generic for Lotronex®)
lubiprostone capsule (generic for Amitiza®)	Amitiza® Capsule
	lbsrela® Tablet
	Lotronex® Tablet
	Motegriv™ Tablet
	Movantik® Tablet
	prucalopride tablet (generic for Motegriv®)
	Symproic® Tablet
	Viberzi® Tablet - T/F of preferred agents not required for Irritable Bowel Syndrome with Diarrhea (IBS-D)

ULCERATIVE COLITIS

Oral

Preferred	Non-Preferred
balsalazide capsule (generic for Colazal®)	Azulfidine® Entab / Tablet
Pentasa® Capsule	budesonide ER tablet (generic for Uceris®)
sulfasalazine IR / DR tablet (generic for Azulfidine® / Entab)	Dipentum® Capsule
	Lialda® Tablet
	mesalamine DR capsule / tablet (generic for Delzicol®, Asacol® HD, Lialda®)
	mesalamine ER capsule (generic for Apriso®, Pentasa®)

ULCERATIVE COLITIS

Rectal

Preferred	Non-Preferred
mesalamine enema (generic for Rowasa®)	budesonide rectal foam
mesalamine suppository (generic for Canasa®)	Canasa® Suppository
SF Rowasa® Enema	mesalamine enema (generic for SF Rowasa®)
	mesalamine kit (generic for Rowasa®)
	Rowasa® Kit

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Stajenza Vial / Syringe (biosimilar to Stelara®), and Yvane® (tocilizumab-sarg) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stepteym® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrikizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

GENTOURINARY / RENAL

ELECTROLYTE DEPLETERS (KIDNEY DISEASE)

Preferred	Non-Preferred
calcium acetate capsule (generic for PhosLo®)	Auryxia® Tablet
calcium acetate tablet (generic for Eliphos®)	ferric citrate Tablet (generic for Auryxia®)
sevelamer carbonate powder pack / tablet (generic for Renvela®)	Fosrenol® Chewable Tablet / Powder Pack
	lanthanum carbonate chewable tablet (generic for Fosrenol®)
	MagneBind® 400 Rx Tablet
	Renvela® Powder Pack / Tablet
	sevelamer hydrochloride tablet (generic for Renagel®)
	Velphoro® Chewable
	Xphozah® Tablet

BENIGN PROSTATIC HYPERPLASIA TREATMENTS

Preferred	Non-Preferred
alfuzosin ER tablet (generic for Uroxatral®)	Cardura® Tablet / XL Tablet
doxazosin tablet (generic for Cardura®)	Cialis® Tablet 5 mg - Clinical criteria apply
dutasteride capsule (generic for Avodart®)	dutasteride / tamsulosin capsule (generic for Jalyn®)
finasteride tablet (generic for Proscar®)	Flomax® Capsule
tamsulosin capsule (generic for Flomax®)	Proscar® Tablet
terazosin capsule (generic for Hytrin®)	Rapaflo® Capsule
	silodosin capsule (generic for Rapaflo®)
	tadalafil tablet (2.5 mg / 5 mg) (generic for Cialis®) - Clinical criteria apply
	Tezruyl™ Oral Solution

URINARY ANTISPASMODICS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
fesoterodine ER tablet (generic for Toviaz®)	darifenacin ER tablet (generic for Enablex®)
oxybutynin solution / syrup / tablet / ER tablet (generic for Ditropan® / XL)	Detrol® Tablet / LA Capsule
solifenacin tablet (generic for Vesicare®)	flavoxate tablet (generic for Urispas®)
tolterodine tablet / ER capsule (generic for Detrol® / LA)	Gentesa® Tablet - T/F of preferred agents not required for diagnosis of dementia or mild cognitive impairment and for patients age ≥65 years
Myrbetriq® ER Tablet	mirabegron ER Tablet (generic for Myrbetriq®) - T/F of preferred agents not required for diagnosis of dementia or mild cognitive impairment and for patients age ≥65 years
	Myrbetriq® Granules- T/F of preferred agents not required for diagnosis of dementia or mild cognitive impairment and for patients age ≥65 years
	oxybutynin tablet (2.5 mg)
	Oxytrol® Patch
	Toviaz® Tablet
	tropium tablet / ER capsule (generic for Sanctura® / XR)
	Vesicare® LS Suspension / Tablet

GOUT

Preferred	Non-Preferred
allopurinol tablet (generic for Zylorin®)	allopurinol tablet (200 mg)
colchicine tablet (generic for Colcrys®)	colchicine capsule (generic for Mitigare®)
probenecid tablet (generic for Benemid®)	Colerys® Tablet
probenecid-colchicine tablet (generic for Col-Benemid®)	febuxostat tablet (generic for Uloric® Tablet)
	Gloperba® Solution
	Krystexxa® Vial
	Mitigare® (branded colchicine 0.6mg) Capsules
	Uloric® Tablet
	Zyloprim® Tablet

HEMATOLOGIC

ANTICOAGULANTS

Injectable

Preferred	Non-Preferred
enoxaparin syringe / vial (generic for Lovenox®)	Arixtra® Syringe
Fragmin® Vial	fondaparinux syringe (generic for Arixtra®)
	Fragmin® Syringe
	Lovenox® Syringe / Vial
	Oral

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
dabigatran capsule (generic for Pradaxa® Capsule)	Pradaxa® Capsule
Eliquis® Tablet / Starter Dose Pack / Sprinkle / Suspension	Pradaxa® Pellet Pack
Jantoven® (branded generic for Coumadin®)	Rivaroxaban tablet / Suspension (generic for Xarelto®)
warfarin tablet (generic for Coumadin®)	Savaysa® Tablet
Xarelto® Starter Pack / Tablet	Xarelto® Suspension

COLONY STIMULATING FACTORS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Fulphila® Syringe	Granix® Safe Syringe / Syringe / Vial
Fylmetra® Syringe	Leukine® Vial
Neupogen® Vial / Syringe	Neulasta® Syringe / Kit
	Nivestym™ Syringe / Vial
	Nvvepria™ Syringe
	Releuko® Syringe / Vial
	Rolvedon™ Syringe
	Ryzneuta® Syringe
	Stimufend® Syringe
	Udenyca® On-Body / Autoinjector / Syringe
	Zarxio® Syringe
	Ziextenzo® Syringe

HEMATOPOIETIC AGENTS

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Aranesp® Syringe / Vial	Mircera® Syringe
Epoetin® Vial	Procrit® Vial
Retacrit® Vial	Reblozyl® Vial
	Vafseo® (vadadastat) Tablet

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Sensesready® Pen / UnReady® Pen / Syringe, Steqyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebgliss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

THROMBOPOIESIS STIMULATING AGENTS	
Preferred	Non-Preferred
Nplate® Vial	Alvaiz™ Tablet
Promacta® Suspension / Tablet	Doptelet Tablet / Sprinkle
	eltrombopag olamine Suspension / Tablet (generic for Promacta®)
	Mulpleta
	Tavalisse™ Tablet
	Wagrilz™ Tablet
OPHTHALMIC ALLERGIC CONJUNCTIVITIS AGENTS	
Preferred	Non-Preferred
azelastine drops (generic for Optivar®)	Alomide® Drops
cromolyn sodium drops (generic for Cromol®)	Alrex® Drops
olopatadine drops (generic for Pataday®, Patanol®)	bepotastine drops (generic for Bepreve®)
olopatadine drops (generic for Pataday®, Patanol®) (OTC)	Bepreve® Drops
	epinastine drops (generic for Elestat®)
	loteprednol drops (generic for Alrex®)
	Zerviate® Drops
ANTIBIOTICS	
Preferred	Non-Preferred
bacitracin-polymyxin ointment (generic for Polysporin®)	Azasite® Drops
ciprofloxacin solution drops (generic for Ciloxan®)	bacitracin ointment (generic for AK-Tracin®)
erythromycin ointment (generic for Ilotycin™)	Besivance® Suspension
gentamicin drops (generic for Garamycin®)	Ciloxan® Ointment
moxifloxacin ophthalmic solution (generic for Vigamox®)	gatitfloxacin drops (generic for Zymaxid®)
ofloxacin drops (generic for Ocuflox™)	Levofloxacin Drops (Generic for Levaquin®)
Polycin® Ointment (branded generic for Polysporin®)	moxifloxacin ophthalmic solution (generic for Moxeza®)
polymyxin-trimethoprim drops (generic for Polytrim®)	Natacyn® Drops
sulfacetamide drops (generic for Bleph-10®)	neomycin-bacitracin-polymyxin ointment (generic for Neosporin® Ophthalmic Ointment)
tobramycin drops (generic for Tobrex®)	neomycin-polymyxin-gramicidin drops (generic for Neosporin® Ophthalmic Drops)
	Neo-Polycin® Ointment (branded generic for Neosporin® Ophthalmic Ointment)
	Ocuflox® Drops
	sulfacetamide ointment (generic for Cetamide®)
	Tobrex® Ointment
	Vigamox® Drops
ANTIBIOTICS-STEROID COMBINATIONS	
Preferred	Non-Preferred
neomycin-polymyxin-dexamethasone drops / ointment (generic for Maxitrol®)	Maxitrol® Drops / Ointment
Tobradex® Ointment	Neo-Polycin® HC (branded generic for Cortisporin®)
tobramycin-dexamethasone suspension (generic for Tobradex®)	neomycin-bacitracin-polymyxin-HC ointment (generic for Cortisporin®)
	neomycin-polymyxin-HC drops (generic for Ocucricin®)
	sulfacetamide-prednisolone drops (generic for Vasocidin®)
	Tobradex® ST Drops
	Zylet® Drops
ANTI-INFLAMMATORY	
Preferred	Non-Preferred
dexamethasone drops (generic for Decadron®)	Acular® Drops / LS Solution
diclofenac drops (generic for Voltaren®)	Acuval™ Solution
difluprednate drops (generic for Durezol®)	bromfenac drops (generic for Prolensa®, Xibrom®, BromSite®)
Flarex® Drops	BromSite® Solution
flurometholone drops (generic for FML®)	Dextenza® Insert
flurbiprofen drops (generic for Ocufen®)	Durezol® Drops
Lotemax® Drops	FML® Forte Drops / Liquifilm® Drops
Nevanac® Droptainer	Illevro® Drops
Pred Mild® Drops	Iluvien® Implant
prednisolone acetate drops (generic for Pred Forte®)	Invetlys® Drops
	ketorolac solution (generic for Acular® / LS)
	Lotemax® Gel / SM Gel / Ointment
	loteprednol drops / gel (generic for Lotemax®)
	Maxidex® Drops
	Ozurdex® Implant
	Pred Forte® Drops
	prednisolone sodium phosphate drops (generic for Inflamm Forte®)
	Prolensa® Drops
	Retisert® Implant
	Triescence® Vial
	Xipere™ (Intraocular)
	Yutiq™ Implant
ANTI-INFLAMMATORY / IMMUNOMODULATOR	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
Restasis® Drops	Cequa™ Drops
Xiidra® Drops	cyclosporine emulsion (generic for Restasis®)
	Evsivis® Drops
	Miebo™ Drops
	Restasis® Multidose™ Drops
	Tryptyr® Drops
	Tyrvaya® Nasal Spray
	Verkazia® Eye Emulsion - T/F of preferred agents not required for diagnosis of vernal keratoconjunctivitis (VKC)
	Vevey® Drops
ALPHA 2 ADRENERGIC AGENTS	
Preferred	Non-Preferred
Alphagan® P Drops	apraclonidine drops (generic for Iopidine®)
brimonidine drops (generic for Alphagan® P)	brimonidine P drops (generic for Alphagan® P)
	Iopidine® Drops

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill FlexPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026.

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starganza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tocilizumab-asag) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Steqyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® (Crohn's Starter Pack / Ped, Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Xylocro® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

BETA BLOCKER AGENTS / COMBINATIONS		
Preferred		Non-Preferred
Combigan® Drops		betaxolol drops (generic for Betoptic®)
timolol drops / GFS gel-solution (generic for Timoptic® / Timoptic XE®)		Betimol® Drops
		Betoptic® S Drops
		brimonidine tartrate / timolol drops (generic for Combigan®)
		carteolol drops (generic for Ocupress®)
		Istalol® Drops
		levobunolol drops (generic for Betagan®)
		timolol hemihydrate (generic for Betimol® drops)
		timolol drop (generic for Istalol® Drops)
		timolol maleate drop (generic for Timoptic® Ocudose® Drops)
		Ocudose® Drops
CARBONIC ANHYDRASE INHIBITORS / COMBINATIONS		
Preferred		Non-Preferred
dorzolamide drops (generic for Trusopt®)		Azopt® Drops
dorzolamide-timolol drops (generic for Cosopt®)		brinzolamide drops (generic for Azopt® Drops)
Simbrinza® Drops		Cosopt® Drops / PF Drops
		dorzolamide-timolol PF drops (generic for Cosopt® PF)
PROSTAGLANDIN AGONISTS		
Preferred		Non-Preferred
latanoprost drops (generic for Xalatan®)		bimatoprost drops (generic for Lumigan® Drops)
Travatan® Z Drops		Durysta® Implant
		iDose® TR Implant
		lyuzeh™ Drops
		Lumigan® Drops
		tafluprost drops (generic for Zioptan®)
		travoprost drops (generic for Travatan® Z)
		Vyzulta® Drops
		Xalatan® Drops
		Xelpros® Drops
		Zioptan® Drops
RHO KINASE MODIFIERS / COMBINATIONS		
Plans may not apply additional utilization management or prior authorization criteria to this category		
Preferred		Non-Preferred
Rhopressa® Drops		
Rocklatan® Drops		
OSTEOPOROSIS		
BONE RESORPTION SUPPRESSION AND RELATED AGENTS		
Preferred		Non-Preferred
alendronate tablet (generic for Fosamax®)		Actonel® Tablet
Bildyos® Syringe (Prolia® Biosimilar)		alendronate solution (generic for Fosamax® Solution)
Forteo® Pen		Atelvia® Tablet
raloxifene tablet (generic for Evista®)		Binosto® Effervescent Tablet
		Bonsity Pen Injector
		calcitonin salmon nasal spray (generic for Miacalcin®)
		Conexence® Syringe (Prolia® Biosimilar)
		Evenity® Syringe
		Evista® Tablet
		Fosamax® Tablet / Plus D Tablet
		ibandronate tablet (generic for Boniva®)
		Jubbont® Syringe (Prolia® Biosimilar)
		Ospomyv™ Syringe (Prolia® Biosimilar)
		Prolia® Syringe
		risedronate DR tablet (generic for Atelvia®)
		risedronate tablet (generic for Actonel®)
		Stoboclo® Syringe (Prolia® Biosimilar)
		teriparatide pen (generic for Forteo®)
		Tymlos® Pen
OTIC		
ANTIBIOTICS		
Preferred		Non-Preferred
ciprofloxacin-dexamethasone suspension (generic for Ciprodex®)		Cipro® HC Suspension
neomycin-polymyxin-hydrocortisone solution / suspension (generic for Cortisporin®)		ciprofloxacin solution (generic for Cetraxal®)
ofloxacin drops (generic for Floxin®)		ciprofloxacin-fluocinolone drops (generic for Otovel®)
		Cortisporin-TC® Suspension
		Otovel® Drops
ANTI-INFECTIVES AND ANESTHETICS		
Preferred		Non-Preferred
acetic acid solution (generic for Vosol®)		acetic acid-hydrocortisone solution (generic for Vosol® HC)
ANTI-INFLAMMATORY		
Preferred		Non-Preferred
fluocinolone 0.01% oil (generic for Dermotic®)		Flac® Otic Oil
		Dermotic® Oil
RESPIRATORY		
BETA-ADRENERGIC HANDHELD, LONG ACTING		
Preferred		Non-Preferred
Serevent® Diskus®		Striverdi® Respimat® Inhalation Spray
BETA-ADRENERGIC HANDHELD, SHORT ACTING		
Preferred		Non-Preferred
albuterol HFA inhaler (generic for Proair® HFA Inhaler / Proventil® HFA Inhaler / Ventolin® HFA Inhaler)		levalbuterol HFA inhaler (generic for Xopenex® HFA Inhaler)
Ventolin® HFA Inhaler		Proair® Digihaler™
Xopenex® HFA Inhaler		Proair® RespiClick®

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Stargemza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tocilizumab-sarg) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Steqemvy® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Xyflo® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

BETA-ADRENERGIC, NEBULIZERS

T/F of only one preferred drug required

Preferred	Non-Preferred
albuterol 0.63mg / 3ml solution (generic for Accuneb®)	arformoterol solution (generic for Brovana®)
albuterol 1.25mg / 3ml solution (generic for Accuneb®)	Brovana® Solution
albuterol sulfate 2.5mg / 0.5ml solution	formoterol solution (generic for Perforomist®)
albuterol sulfate 2.5mg / 3ml solution	levabuterol solution / concentrate solution (generic for Xopenex® / Concentrate)
	Perforomist® Solution

BETA-ADRENERGIC, ORAL

Preferred	Non-Preferred
albuterol tablets (generic for Proventil® Repetabs)	albuterol ER tablets (generic for VoSpire® ER)
albuterol syrup (generic for Ventolin® Syrup)	
terbutaline tablet (generic for Brethine®)	

ORALLY INHALED ANTICHOLINERGICS / COPD AGENTS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Anoro® Ellipta® Inhaler	Bevespi® Aerosphere®
Atrovent® HFA Inhaler	Daliresp® Tablet
Combivent® Respimat® Inhalation Spray	Duaklir® Pressair®
Incruse® Ellipta® Inhaler	Ohtuvayre™ Inhalation suspension
ipratropium nebulizer solution (generic for Atrovent®)	tiotropium inhaler (generic for Spiriva® Handihaler®)
ipratropium / albuterol solution (generic for Duoneb®)	Tudorza® Pressair® Inhaler
roflumilast tablet (generic for Daliresp®)	Umeclidinium-Vilanterol Inhaler (generic for Anoro®)
Spiriva® Handihaler® / Respimat® Inhalation Spray	Yupelri™ Solution
Stiolto® Respimat® Inhalation Spray	

INHALED CORTICOSTEROIDS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Alvesco® Inhaler	ArmonAir™ DigiHaler™
Arnuity® Ellipta® Inhaler	fluticasone furoate DPI (generic for Arnuity Ellipta™)
Asmanex® HFA Inhaler / Twisthaler®	fluticasone propionate diskus (generic for Flovent® Diskus)
budesonide suspension 0.25mg, 0.5mg, 1mg (generic for Pulmicort® Respules)	Pulmicort® Respules 0.25mg, 0.5mg, 1mg
fluticasone propionate HFA (generic for Flovent® HFA)	
Pulmicort® Flexhaler	
QVAR® RediHaler™	

INHALED CORTICOSTEROID COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Advair® Diskus®	AirDuo® DigiHaler™ / RespiClick®
Advair® HFA Inhaler	AirSupra™ Inhaler
Dulera® Inhaler	Breo® Ellipta®
Symbicort® Inhaler	Breyna™ Inhaler
	Breztri™ Aerosphere™
	budesonide / formoterol inhalation (generic for Symbicort®)
	fluticasone / salmeterol HFA inhaler (generic for Advair® HFA)
	fluticasone / salmeterol inhalation (generic for Advair® Diskus®)
	fluticasone / salmeterol inhalation (generic for AirDuo®)
	fluticasone / vilanterol inhalation (generic for Breo® Ellipta®)
	Trelegy® Ellipta®
	Wixela™ Inhub™

INTRANASAL RHINITIS AGENTS

Preferred	Non-Preferred
	T/F of preferred agents not required in children < 4 years of age for steroid-containing products
	azelastine nasal spray (generic for Astepro®)
azelastine spray (generic for Astelin®)	azelastine-fluticasone nasal spray (generic for Dymista®)
Dymista® Nasal Spray	flunisolide nasal spray (generic for Nasalide®)
fluticasone spray (generic for Flonase®)	mometasone nasal spray (generic for Nasonex®)
ipratropium spray (generic for Atrovent® Nasal)	Omnaris® Nasal Spray
olopatadine nasal spray (generic for Patanase®)	Patanase® Nasal Spray
	QNASL® Nasal Spray / Children's Spray
	Rvaltris® Nasal Spray
	Sinuva™ Implant
	Xhance™ Nasal Spray
	Zetonna® Nasal Spray

LEUKOTRIENE MODIFIERS

Preferred	Non-Preferred
montelukast chewable / tablet (generic for Singulair®)	Accolate® Tablet
	montelukast granules (generic for Singulair®)
	Singulair® Chewable / Granules / Tablet
	zafirlukast tablet (generic for Accolate®)
	zileuton tablet (generic for Zylflo®)
	Zylflo® Filmtab

LOW SEDATING ANTIHISTAMINES

Preferred	Non-Preferred
cetirizine OTC syrup 1mg/1ml (generic for Zyrtec® OTC Syrup)	cetirizine chewable tablet OTC (generic for Zyrtec® OTC Tablet)
cetirizine Rx syrup (generic for Zyrtec® Syrup)	cetirizine OTC syrup 5mg/5ml (generic for Zyrtec® OTC Syrup)
cetirizine tablets OTC (generic for Zyrtec® OTC Tablet)	cetirizine OTC softgel
levocetirizine OTC tablet (generic for Xyzal® OTC Tablet)	Clarinetx® Tablet - T/F of preferred agents not required for children < 2 years of age
levocetirizine Rx tablet (generic for Xyzal® Rx Tablet)	desloratadine ODT / Tablet (generic for Clarinetx®) - T/F of preferred agents not required for children < 2 years of age
loratadine tablet OTC (generic for Claritin® OTC)	fexofenadine OTC suspension / OTC tablet (generic for Allegra® OTC)
	levocetirizine Rx solution (generic for Xyzal® Rx Solution)
	loratadine OTC chewable ODT / solution (generic for Claritin® OTC)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenzia Vial / Syringe (biosimilar to Stelara®), and Tyneo® (teclitinumab-aszg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroycma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebgliss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs/prescription-drugs/outpatient-pharmacy-services>

LOW SEDATING ANTIHISTAMINE COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

Quantity limit of 102 days supply per 12 months apply to all drugs in this class

Preferred	Non-Preferred
loratadine-D OTC tablet (generic for Claritin-D® OTC)	cetirizine-D OTC tablet (generic for Zyrtec-D® OTC) Clarinet-D® Tablet fexofenadine-D 12 Hour OTC Tablet (generic for Allegra-D® 12 Hour OTC) fexofenadine-pseudoephedrine ER 24 hour tablet (generic for Allegra-D® 24 hour)

FIRST GENERATION ANTIHISTAMINES

Preferred	Non-Preferred
carbinoxamine solution Carbazol Solution cyproheptadine syrup / tablet hydroxyzine capsule / solution / tablet	carbinoxamine tablet clemastine tablet (generic for Clemenza™) Clemenza™ Tablet Karbinal™ ER Suspension - T/F of immediate release carbinoxamine solution and cetirizine syrup required for coverage RyClora™ Solution RyVent™ Tablet Vistaril® Capsule

TOPICALS

ACNE AGENTS

Preferred	Non-Preferred
adapalene / benzoyl peroxide (generic for Epiduo® Forte) adapalene / benzoyl peroxide (generic for Epiduo® Gel) adapalene gel (generic for Differin®) azelaic acid gel (generic for Finacea®) clindamycin lotion (generic for Cleocin-T®) clindamycin phosphate pledgets / solution (generic for Cleocin-T®) clindamycin-benzoyl peroxide gel (generic for Benzaclicin®, Neucac®) Differin® gel pump Differin® lotion/cream Epiduo® gel pump erythromycin gel (generic for Emcin®, Erycette®, EryGel®, et. al.) erythromycin solution (generic for Emcin®, EryDerm®, EryMax®, et. al.) erythromycin-benzoyl peroxide gel (generic for Benzamycin®) Finacea® Gel	adapalene cream / gel pump generic for Differin®) Aklief® Avar® Cleanser / LS Cleanser Avar-E® Emollient Cream / Green Emollient Cream / LS Cream BP® 10-1 Wash / Cleansing Wash ClearAclyic / ClearAclyic Pro Cleocin® T Lotion Clindacin® ETZ Pledget / Kit / P Foam / P Pledgets / PAC Kit Clindagel® Gel clindamycin / tretinoin (generic for Veltin®) clindamycin phosphate foam (generic for Evoclin®) clindamycin phosphate gel (Clindagel®) clindamycin-benzoyl peroxide pump (generic for Acanya®) clindamycin-benzoyl peroxide pump (generic for Benzaclicin®) clindamycin-benzoyl peroxide pump (generic for Onexton®) dapsonse gel / gel pump (generic for Aczone® Gel) Epiduo® Forte gel pump Ery® Pads Erygel® Gel Evoclin® Foam Fabor® Foam Finacea® Foam Neucac® Gel / Kit Ovace® Plus Cleansing Cream / Gel / Lotion / Shampoo / Wash Rosnil Cleanser lotion Rosula® Cloths / Wash sodium sulfacetamide cleanser / cream (generic for Avar® / LS) sodium sulfacetamide lotion (generic for Klaron™) sodium sulfacetamide shampoo, wash (generic for Ovace® / Plus) sodium sulfacetamide-sulfur lotion / suspension (generic for Novacet®, Plexion®, Zetacet®) sodium sulfacetamide-sulfur pad / suspension / wash (generic for Sumaxin®) SSS® 10-5 Cream / Foam sulfacetamide-sulfur 9-4% cleanser (generic for Zencia™) sulfacetamide-sulfur cream (generic for Avar® E, SSS® 10-5) Sumadan® Kit / XLT Kit / Wash Sumaxin® Cleansing Pads / CP Kit / TS Topical Suspension / Wash tazarotene cream / foam / gel (generic for Tazorac®, Fabor®) tretinoin cream / gel (generic for Retin-A®) tretinoin microsphere gel / microsphere gel pump (generic for Retin-A® Micro) Twyneo® Cream Winlevi® Cream Zma Clear® Cleanser

ANDROGENIC AGENTS

Preferred	Non-Preferred
AndroGel® Pump testosterone gel pump (generic for AndroGel®)	Natesto® Nasal Gel Testim® Gel testosterone gel pump (generic for Fortesta®, Axiron®) testosterone packet (generic for AndroGel®) Vogelxo® Gel / Packet / Pump

NSAIDS

Preferred	Non-Preferred
diclofenac topical gel (generic for Voltaren® Gel) diclofenac solution (generic for Pennsaid®)	diclofenac epolamine patch (generic for Flector®) diclofenac pump (generic for Pennsaid®) Pennsaid® Solution Packet / Pump

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectables: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjamza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (teflinmab-aszg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroycma® (ustokinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quellent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytro® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebricitumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

ANTIBIOTICS	
Preferred	Non-Preferred
gentamicin cream / ointment (generic for Garamycin®)	Centany® AT Ointment Kit / Ointment
mupirocin ointment (generic for Bactroban®)	mupirocin cream (generic for Bactroban®)
	Xepi™ Cream
ANTIBIOTICS - VAGINAL	
Plans may not apply additional utilization management or prior authorization criteria to this category	
Preferred	Non-Preferred
Cleocin® Vaginal Ovules	Cleocin® Vaginal Cream
clindamycin vaginal cream (generic for Cleocin® Vaginal Cream)	metronidazole vaginal gel (generic for Nuvessa® Vaginal Gel)
Chlidesse® Vaginal Cream	Vandazole™ Vaginal Gel
metronidazole vaginal gel (generic for Metrogel® Vaginal Gel)	Xaciato® Vaginal Gel
Nuversa® Vaginal Gel	
ANTIFUNGALS	
Preferred	Non-Preferred
ciclopirox cream / solution (generic for Loprox®, Penlac®)	Ciclodan® Cream / Cream Kit / Kit / Solution
clotrimazole Rx cream (generic for Lotrimin® Rx)	ciclopirox gel / shampoo / suspension (generic for Loprox®)
clotrimazole-betamethasone cream (generic for Lotrisone®)	ciclopirox treatment kit (generic for Ciclodan®)
ketoconazole cream / shampoo (generic for Nizoral®)	clotrimazole Rx solution (generic for Lotrimin® Rx)
Klayesta® Powder (branded generic for Nystop®)	clotrimazole-betamethasone lotion (generic for Lotrisone®)
Nyamyce® Powder (branded generic for Nystop®)	econazole cream (generic for Spectazole®)
nystatin cream / ointment / powder (generic for Mycostatin®, Nystop®)	econazole foam (generic for Ecoza®)
Nystop® Powder	Ertaczo® Cream
nystatin-triamcinolone cream / ointment (generic for Myceolog II®)	Extina® Foam
	ketoconazole foam (generic for Extina®)
	Ketodan® Foam / Foam Kit
	Loprox® Suspension / Cream / Kit
	luliconazole cream (generic for Luzu®)
	micronazole / zinc oxide / petrolatum ointment (generic for Vusion®) - Clinical criteria apply
	naftifine cream / gel (generic for Nafin®)
	Nafin® Gel
	oxiconazole cream (generic for Oxistat®)
	Oxistat® Lotion
	salicylic acid ointment (generic for Bensal HP®)
	tavaborole topical solution (generic for Kerydin®)
	Vusion® Ointment - Clinical criteria apply
ANTIPARASITICS	
Plans may not apply additional utilization management or prior authorization criteria to this category	
T/F of only one preferred drug required	
Preferred	Non-Preferred
Natroba® Topical Suspension	Crotan™ Lotion
permethrin cream (generic for Elimite®)	Elimite™ Cream
	Eurax® Cream / Lotion
	malathion lotion (generic for Ovide®)
	Ovide® Lotion
	Pruradik™ Lotion
	Sklice® Lotion
	spinosad topical suspension (generic for Natroba®)
ANTIVIRAL	
Preferred	Non-Preferred
acyclovir Cream / Ointment (generic for Zovirax®)	penciclovir cream (generic for Denavir®)
Denavir® Cream	
Imidazoquinolinamines	
Preferred	Non-Preferred
imiquimod cream packet (generic for Aldara®)	Condylox® Gel
	Hylfor™ Gel
	imiquimod cream / cream pump (generic for Zyclara®)
	podofilox gel / solution (generic for Condylox®)
	Veregen® Ointment
PSORIASIS	
Preferred	Non-Preferred
calcipotriene cream / solution (generic for Dovonex®)	calcipotriene ointment / foam (generic for Dovonex®, Sorilux®)
calcipotriene-betamethasone suspension / ointment (generic for Talconex®)	calcitriol ointment (generic for Vectical®)
Vtama® Cream	Enstilar® Foam
	Sorilux® Foam
	Talconex® Ointment / Suspension
	Vectical Ointment
	Zoryve® 0.3% Cream / Foam
ROSACEA AGENTS	
Preferred	Non-Preferred
azelaic acid gel (generic for Finacea®)	brimonidine gel pump (generic for Mirvaso®)
Finacea® Gel	Epsoly® (benzoyl peroxide)
metronidazole cream (generic for MetroCream®)	Finacea® Foam
metronidazole gel / pump (generic for MetroGel®)	ivermectin cream (generic for Soolantra®)
Rosadan® Cream / Gel	MetroCream®
	MetroGel®
	metronidazole lotion (generic for MetroLotion®)
	Mirvaso® (brimonidine)
	Rhofade® Cream
	Rosadan® Kit
	Soolantra™ Cream

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® / Vial to preferred status in the Hypoglycemic-Injectables: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyenna® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® SensorReady® Pen / UnoReady® Pen / Syringe, Stroyvyn® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblys™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

STEROIDS

Low Potency

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
desonide cream / ointment (generic for DesOwen®)	alclometasone dipropionate cream / ointment (generic for Aclovetate®)
DermaSmoothe® FS Scalp and Body Oil	Capex®
hydrocortisone cream / lotion / ointment (generic for Hytone®)	desonide lotion (generic for DesOwen® Lotion)
	fluocinolone body / scalp oil (generic for DermaSmoothe® FS Scalp / Body Oil)
	Hydrocortisone Solution
	Hydroxym™ Gel
	Texacort® Solution

Medium Potency

Preferred	Non-Preferred
fluticasone cream / ointment (generic for Cutivate®)	Beser™ Lotion / Kit
mometasone cream / ointment / solution (generic for Elocon®)	clocortolone cream (generic for Cloderm®)
	fluocinolone cream / ointment / solution (generic for Synalar®)
	flurandemolide Lotion / Ointment
	fluticasone lotion (generic for Cutivate® Lotion)
	hydrocortisone butyrate cream / lipid cream / lotion / ointment / solution (generic for Locoid®)
	hydrocortisone valerate cream / ointment (generic for Westcort®)
	Pandel® Cream
	prednicarbate cream / ointment (generic for Dermatop®)
	Synalar® Cream / Ointment / Kit / Solution / TS Kit

High Potency

Preferred	Non-Preferred
betamethasone valerate cream / ointment (generic for Valisone®)	amcinonide cream (generic for Cyclocort®)
fluocinonide cream / gel / ointment / solution (generic for Lidex®)	betamethasone dipropionate augmented cream / gel / lotion / ointment (generic for Diprolone®)
triamcinolone acetonide cream / lotion / ointment (generic for Kenalog®)	betamethasone dipropionate cream / lotion / ointment (generic for Diprosone®)
	betamethasone valerate foam / lotion (generic for Valisone®)
	desoximetasone cream / gel / ointment / spray (generic for Topicort®)
	diflorasone cream / ointment (generic for Florone®)
	Diprolene® Ointment
	fluocinonide emollient cream (generic for Lidex® E)
	halcinonide cream (generic for Halog®)
	halcinonide solution (generic for Halog®)
	Halog® Cream
	Kenalog® Spray
	Topicort® Cream / Gel / Ointment / Spray
	triamcinolone sprav (generic for Kenalog®)

Very High Potency

Preferred	Non-Preferred
clobetasol cream / emollient cream / gel / ointment (generic for Temovate®)	ApexiCon® E Cream
clobetasol shampoo (generic for Clobex®)	clobetasol foam / emollient foam / emulsion foam (generic for Olux® / Olux-E®)
clobetasol solution (generic for Cormax®)	clobetasol lotion / spray (generic for Clobex®)
halobetasol propionate cream / ointment (generic for Ultravate®)	Clobex® Shampoo / Spray
	Clodan® Kit / Shampoo
	halobetasol propionate foam (generic for Lexette®)
	Lexette® Foam
	Olux® Foam
	Tovet™ Foam / Foam Kit
	Ultravate® Lotion

MISCELLANEOUS

Uterine Disorder Treatments

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Oriahnn® Capsule	
Orilissa® Tablet	
Myfembree® Tablet	

Urea Cycle Disorder Treatments, Oral

Plans may not apply additional utilization management or prior authorization criteria to this category

T/F of only one Preferred drug required

Preferred	Non-Preferred
Buphenyl® Tablet/Powder	carglumic acid Tablet for oral suspension (generic for Carbaglu®)
Carbaglu® Tablet for oral suspension	glycerol phenylbutyrate oral liquid (generic for Ravicti®) T/F of preferred drug is not required for Urea cycle disorder
	Olpruva™ Suspension
	Pheburane® Oral Pellets
	Ravicti® Liquid T/F of preferred drug is not required for Urea cycle disorder
	sodium phenylbutyrate Tablet/Powder (generic for Buphenyl®)

WEIGHT MANAGEMENT AGENTS

GLP-1 Receptor Agonists indicated for the treatment of obesity (Incretin Mimimetics)

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Wegovy® Pen/Tablet	Saxenda® (tiraglutide) Pen
	Zepbound® (tirzepatide) Pen

Weight Management (Non-Incretin Mimimetics)

Preferred	Non-Preferred
diethylpropion tablet / ER tablet	benzphetamine tablet
phendimetrazine tablet / ER capsule	orlistat capsule (generic for Xenical®)
phentermine tablet / capsule	phentermine/Topiramate Capsule (generic for Qsymia®)
	Xenical® (orlistat) Capsule

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill®/EliPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Stajenza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Steyemx® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrikizumab-ibkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

IMMUNOMODULATORS, ASTHMA

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Fasenra® Pen / Syringe	Cinqair® Vial
Xolair® (omalizumab) Autoinjector/Syringe	Nucala® Syringe / Vial / Autoinjector
	Tezspire® Pen / Syringe - T/F of preferred agents not required for diagnosis of non-allergic, non-eosinophilic severe asthma
	Xolair® Vial

IMMUNOMODULATORS, Atopic Dermatitis

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Adhry® Syringe / Autoinjector	Anzuppo® Cream
Dupixent® Pen / Syringe	Cibinqo™ Tablet
Ebglvys™ (lebrikizumab-ibkz) Syringe/Pen	Nemluvio® Pen
Eucrisa® 2% Ointment	Opzelura™ Cream
pimecrolimus cream (generic for Elidel®)	Zoryve® (roflumilast) 0.05% Cream
tacrolimus ointment (generic for Protopic®)	Zoryve® (roflumilast) 0.15% Cream

ANTIPSORIATICS, ORAL

Preferred	Non-Preferred
acitretin (generic for Soriatane®)	methoxsalen rapid (generic for Oxsoalen-Ultra®)

EPINEPHRINE, SELF ADMINISTERED

Plans may not apply additional utilization management or prior authorization criteria to this category

Quantity limits apply to all drugs in this class

Preferred	Non-Preferred
Auvi-Q® Auto Injector	
epinephrine auto injector (generic for Epi-Pen® / Epi-Pen® Jr/ Adrenaclick®)	
Epi-Pen® Auto Injector / 2-Pak / Jr. Auto Injector / Jr. 2-Pak	
neffy® nasal spray	

ESTROGEN AGENTS, COMBINATIONS

Preferred	Non-Preferred
Activella® Tablet	Abigale™ Lo Tablet
Amabelz™ Tablet	Biiuva® Capsule
estradiol/norethindrone tablet (generic for Activella®)	
Fyavolv™ Tablet	
Jinteli® (branded generic for FemHRT®)	
Mimvey® / Lo (branded generic for Activella®)	
norethindrone-ethinyl estradiol (generic for FemHRT®)	
Premphase® Tablet	
Prempro® Tablet	

ESTROGEN AGENTS, ORAL / TRANSDERMAL

Preferred	Non-Preferred
Climara® Pro Patch	Climara® Patch
CombiPatch® Patch	Divigel® Gel Packet
estradiol patch (generic for Climara®, Menostar®, Vivelle-Dot®)	Doti™ Patch
estradiol tablet (generic for Estrace®)	Duavee® Tablet
Evamist® Spray	Elestrin® Gel
Menest® Tablet	Estrace® Tablet
Premarin® Tablet	Estradiol Gel Pump
	estradiol gel packet (generic for Divigel®)
	Lyllana™ Patch
	Menostar® Patch
	Minivelle® Patch
	Osphena® Tablet
	Veozah™ Tablet
	Vivelle-Dot® Patch

ESTROGEN AGENTS, VAGINAL PREPARATIONS

Preferred	Non-Preferred
estradiol vaginal cream (generic for Estrace®)	Estrace® Cream
Estring® Vaginal Ring	estradiol tablet (generic for Vagifem®)
Premarin® Vaginal Cream	Femring® Vaginal Ring
Vagifem® Vaginal Tablet	Invexxy® Vaginal Inserts
	Yuvaferm® Vaginal Tablet

GLUCOCORTICOID STEROIDS, ORAL

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
budesonide EC capsule (generic for Entocort® EC)	Alkindi® Sprinkle Capsule
dexamethasone elixir / tablet (generic for Decadron®)	Agamree® Suspension
dexamethasone solution (generic for Concedix®)	Cortef® Tablet
Emflaza® Tablet / Suspension - Clinical criteria apply	cortisone tablet (generic for Patison®)
hydrocortisone tablet	deflazacort suspension (generic for Emflaza®) - Clinical criteria apply. T/F of preferred agents not required for children < 12 years of age.
methylprednisolone 4mg dosepack / tablet (generic for Medrol®)	deflazacort tablet (generic for Emflaza®) - Clinical criteria apply
prednisolone sodium phosphate solution (generic for PediaPred®, OraPred®, Veripred®)	dexamethasone tablet dosepack / Intensol® Drops
prednisolone solution (generic for Prelone®, Millipred®)	Exhilia® Suspension- T/F of preferred agents not required for diagnosis of eosinophilic esophagitis
prednisone dose pack (generic for Sterapred®)	Hemady™ Tablet
prednisone solution / tablet (generic for Deltasone®)	Jaythari Tablet (generic for Emflaza®)
	Khindivi™ Solution
	Medrol® Dose Pack / Tablet
	methylprednisolone 8mg / 16mg / 32mg tablet (generic for Medrol®)
	Millipred® Dose Pack / Tablet
	prednisolone ODT (generic for OraPred® ODT)
	prednisolone tablet
	Prednisone Intensol® Concentrated Solution
	Rayos® Tablet
	Taperdex® Tablet
	Tarpeyo™ Capsule - T/F of preferred agents not required for diagnosis of IgA nephropathy
	Pvquvi™ Suspension

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Elquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill FlexPen® Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Starjamza Vial / Syringe (biosimilar to Stelara®), and Tyenne® (tocilizumab-aazg) Autoinjector / Syringe / Vial to preferred status; moved Cosentyx® SensorReady® Pen / UnoReady® Pen / Syringe, Steqyma® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Qualient), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglvys™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

CYTOKINE AND CAM ANTAGONISTS

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

T/F of only one Preferred drug required

Preferred	Non-Preferred
adalimumab-adbm Pen/Psoriasis-UV Pen/Crohn's Pen/Syringe (Manufacturer: Boehringer-Ingelheim)	Abrilada™ Pen / Syringe
Enbrel® Mini Cartridge / Sureclick® Syringe / Syringe / Vial	Actemra® ACTPen™ / Syringe / Vial
Hadlima™ Syringe / PushTouch	adalimumab-aacF Pen / Psoriasis-UV Pen / Crohn's Pen / Syringe
infliximab vial (generic for Remicade®)	adalimumab-aaty Autoinjector / Syringe
Otezla® Starter Pack / Tablet	adalimumab-adaz Pen / Syringe
Pyzchiva® (ustekinumab-twe) Syringe/Vial	adalimumab-adbm Pen/Syringe (Manufacturer: Qualient)
Starjamza Vial / Syringe (biosimilar to Stelara®)	adalimumab-ikjp Pen / Syringe
Taltz™ Auto-injector / Syringe	adalimumab-ryvk Autoinjector / Syringe
Tyenne® (tocilizumab-aazg) Autoinjector / Syringe/ Vial	Amjevita™ Syringe / Autoinjector
Xeljanz® Tablet	Arcalyst® SQ Syringe
	Avsola® Vial
	Avtozma® Vial
	Binzelx® Autoinjector / Syringe
	Cimzia™ Starter Kit / Syringe Kit / Vial Kit
	Cosentyx® SensorReady® Pen / UnoReady® Pen / Syringe/ Vial
	Cyltezo™ (adalimumab-adbm) Psoriasis-UV Pen
	Cyltezo™ Syringe / Crohn's-UC-HS Pen / Psoriasis Pen / Pen
	Enspryng™ Syringe
	Entyvio® Pen / Vial
	Hulio™ Pen / Syringe
	Humira™ Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe
	Hyrmoz™ Pen / Crohn's-UC Pen / Ped. Crohn's Pen / Syringe / Psoriasis Pen
	Idacio® Pen / Psoriasis Pen / Crohn's-UC Pen / Syringe
	Ilaris® Vial
	Ilumya® Syringe
	Imuldosa™ Syringe/Vial
	Inflextra™ Vial
	Kevzara™ Syringe / Pen
	Kineret® Syringe - T/F of preferred agents not required for diagnosis of Neonatal Onset Multi-System Inflammatory Disease
	Olumiant® Tablet
	Omvoh™ (mirikizumab-mrkz) Syringe / Pen / Vial
	Orencia® Clickjet® / Syringe/ Vial
	Otezla® XR Initiation Pack / Tablet
	Otulfli® Syringe/Vial
	Remicade® Vial
	Renflexis™ Vial
	Rinvoq® (upadacitinib) LQ Solution
	Rinvoq® ER Tablet
	Selarsdi™ Vial / Syringe
	Simlanti® Autoinjector/kit
	Simponi® Pen / Syringe / Aria® Vial
	Skyrizi® On-Body / Vial / Pen / Syringe
	Sotyktu® Tablet
	Spevigo® Vial / Syringe
	Stelara® Syringe / Vial T/F of preferred ustekinumab is required
	Steqyma™ (ustekinumab-stba) Vial/Syringe
	Toifidence™ (tocilizumab-bavi) Vial
	Tremfya® Syringe / Injector/ Vial / Pen Induction PK-Crohn
	Uplizna® Vial
	ustekinumab Vial / Syringe (generic for Stelara®)
	ustekinumab-aekn syringe (generic for Stelara®/Selarsdi B™)
	Ustekinumab-twe Vial / Syringe (generic for Pyzchiva®)
	Velsipity® Tablet
	Xeljanz™ Solution / XR Tablet
	Yesintek™ Syringe/Vial
	Yuflyma® Syringe / Autoinjector / Crohn's-UC-HS Autoinjector
	Yusimry™ Pen
	Zymfentra™ Pen / Syringe

IMMUNOSUPPRESSANTS

Preferred	Non-Preferred
Astagraf® XL Capsule	
azathioprine tablet (generic for Imuran®)	
Celcept® Capsule / Suspension / Tablet	
cyclosporine capsule (generic for Sandimmune®)	
cyclosporine modified capsule / solution (generic for Gengraf®, Neoral®)	
Envarsus® XR Tablet	
everolimus tablet (generic for Zortress® Tablet)	
Gengraf® Capsule / Solution	
Imuran® Tablet	
mycophenolate capsule / suspension / tablet (generic for Celcept®)	
mycophenolic acid tablet (generic for Myfortic®)	
Myfortic® tablet	
Myhibbin™ (mycophenolate mofetil) Suspension	
Neoral™ Capsule / Solution	
Prograf® Capsule / Granule Packet	
Rapamune® Tablet	
Rezurock™ Tablet	
Sandimmune® Capsule / Solution	
sirolimus tablet / solution (generic for Rapamune®)	
tacrolimus capsule (generic for Hecloria®, Prograf®)	
Tavneos® Capsule	
Zortress® Tablet	

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill® FlexPen® Vial to preferred status in the Hypoglycemic-Injectables: Rapid acting Insulin category, due to patient access, effective 03.20.2026.

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-Injector / Syringe, Starjenza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-sarg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® Seasonready® Pen / UnReady® Pen / Syringe, Stroycym® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® (Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Eblyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

MOVEMENT DISORDERS

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Austedo® Tablet	Xenazine® Tablet
Austedo® XR Tablet / Titration Kit	
Ingrezza® (valbenazine) Sprinkle Capsules	
Ingrezza® Capsule / Initiation Pack	
tetrabenazine tablet	

HEREDITARY ANGIOEDEMA (HAE) PROPHYLAXIS AGENTS

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Haegarda® Vial	Cinryze® Vial
Orladevo® Capsule	Dawnzera™ Auto syringe
	Takhzyro® Vial / Syringe

HEREDITARY ANGIOEDEMA (HAE) TREATMENT AGENTS

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all drugs in this class

Preferred	Non-Preferred
Beriner® Vial / Kit	Ekerly® Tablet
icatibant syringe (generic for Firazyr®)	Andemby® Auto Injector
Kalbitor® Vial	Firazyr® Syringe
Sajazir™ Syringe (branded generic for icatibant)	Ruconest® Vial

OPIOID ANTAGONISTS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Kloxxado™ Nasal Spray	
LifEMS™ naloxone Syringe Kit	
naloxone nasal spray (OTC)	
naloxone syringe / spray / vial (generic for Narcan®)	
naltrexone tablet	
Narcan® Nasal Spray (OTC)	
Opvee® Nasal Spray	
Rextovy™ (naloxone) Nasal Spray	
Vivitrol™ Vial / Diluent	
Zimhi™ Syringe	
Zurnai™ Injection	

OPIOID DEPENDENCE

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Prior Approval Not Required for Coverage of Preferred Agents	Clinical Criteria Apply to Non-Preferred Agents
Brixadi™ Weekly Syringe / Monthly Syringe	buprenorphine-naloxone SL film (generic for Suboxone®)
buprenorphine-naloxone SL tablet (generic for Suboxone®)	Lofexidine Tablet T/F of preferred agents not required for diagnosis of opioid withdrawal
buprenorphine SL tablet (generic for Subutex®)	Lucemyra® Tablet - T/F of preferred agents not required for diagnosis of opioid withdrawal
Suboxone® SL Film	Zubsolv® Tablet SL
Sublocade® Syringe	

SKELETAL MUSCLE RELAXANTS

Preferred	Non-Preferred
baclofen tablet (generic for Lioresal®)	Amrix® ER Capsule
cyclobenzaprine tablet (generic for Flexeril®)	baclofen oral solution
methocarbamol tablet (generic for Robaxin®)	baclofen suspension (generic for Fleqsuvy™)
tizanidine tablet (generic for Zanaflex®)	chlorzoxazone tablet (generic for Parafon Forte®)
	cyclobenzaprine ER capsule (generic for Amrix® ER)
	Dantrium® Capsule / Vial
	dantrolene sodium capsule (generic for Dantrium®)
	Fexmid® Tablet
	Fleqsuvy™ Suspension
	Lorzone® Tablet
	Lyvispah® Granule Packet
	metaxalone tablet (generic for Skelaxin®)
	Norgesic™ Tablet / Forte Tablet
	orphenadrine / aspirin / caffeine tablet (generic for Norgesic™)
	orphenadrine citrate tablet / vial (generic for Norflex®)
	Orphenesic® Forte Tablet
	Ozobax DS® Solution
	Ozobax® Solution
	Robaxin® Vial
	Tanlor® Tablet
	tizanidine capsules (generic for Zanaflex®)
	Zanaflex® Capsule / Tablet

DISPOSABLE INSULIN DELIVERY DEVICES

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
CeQur Simplicity™	
CeQur Simplicity™ Inserter	
llet Infusion Kit	
llet Starter Kit	
Omnipod 5® DexG7/G6 Intro Kit/Pods (GEN5), FSL2 G6 Intro Kit/Pods	
Omnipod DASH® Pods (5-Pack) / Intro Kit	
Omnipod GO™ Pods	

DIABETIC CONTINUOUS GLUCOSE MONITOR SUPPLIES

Continuous Glucose Monitor Transmitters / Receivers / Readers

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all items in this class

Preferred	Non-Preferred
Dexcom G6® Transmitter / Receiver	Freestyle Libre™ 14 day Reader
Dexcom G7® Receiver	
Freestyle Libre™ 2 Reader	
Freestyle Libre™ 3 Reader	

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)

Effective Date April 1, 2026

Revised 02.19.2026 Off-Cycle Change: Added Eliquis® Sprinkle and Suspension to preferred status in the Oral Anticoagulants category due to fiscal impact, effective 01.01.2026.

Revised 03.18.2026 Off-Cycle Change: Moved Novolog® U-100 Penfill/ FlexPen® / Vial to preferred status in the Hypoglycemic-Injectable: Rapid acting Insulin category, due to patient access, effective 03.20.2026

Revised 03.31.2026 Off-Cycle Change: Moved Taltz® Auto-injector / Syringe, Stargemza Vial / Syringe (biosimilar to Stelara®), and Tyneo® (tocilizumab-sazg) Autoinjector / Syringe/ Vial to preferred status; moved Cosentyx® SensoReady® Pen / UnoReady® Pen / Syringe, Stegvy® (ustekinumab-stba) Vial / Syringe, adalimumab-adaz Pen / Syringe, adalimumab-adbm Pen/Syringe (Manufacturer: Quallent), and Humira® Crohn's Starter Pack / Ped. Crohn's Starter Pack / Pen / Psoriasis Starter Pack / Syringe to non-preferred in the Cytokine and CAM Antagonists category; moved Skytrofa® Cartridge to preferred and removed the red writing T/F (Trial/Failure) of preferred agents not being required for children <18 years of age in the Growth Hormone category; moved Ebglyss™ (lebrizumab-bkz) Syringe / Pen to preferred in the immunomodulators, Atopic Dermatitis category; added Wegovy® Tablet as preferred in the GLP-1 weight management category, and moved Vtama® Cream to preferred in the Psoriasis category due to fiscal impact, effective 04.01.2026.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Continuous Glucose Monitor Sensors

Plans may not apply additional utilization management or prior authorization criteria to this category

Clinical criteria apply to all items in this class

Preferred	Non-Preferred
Freestyle Libre™ 2 Sensor	Freestyle Libre™ 14 day Sensor
Freestyle Libre™ 2 Plus Sensor	
Freestyle Libre™ 3 Sensor	
Freestyle Libre™ 3 Plus Sensor	
Dexcom G6® Sensor	
Dexcom G7® Sensor (10 day sensor and 15 day sensor)	

DIABETIC SUPPLIES

Plans may not apply additional utilization management or prior authorization criteria to this category

N.C. Medicaid only covers, at point of sale, the designated preferred products listed below for blood glucose meters, diabetic test strips, control solutions, lancets, and lancing devices for Medicaid-primary recipients (dually eligible and third-party recipients are not affected). These products are covered under the Outpatient Pharmacy Program and can be submitted to the pharmacy point-of-sale system with a prescription. Diabetic supplies, including other brands, can also be submitted under Durable Medical Equipment using the NDC and HCPCS code. Beneficiaries are allowed 1 covered meter every 2 years (730 days). For questions or assistance regarding diabetic supplies for Medicaid Direct members, please call the NC Tracks call center at 1-800-688-6696. ***All blood glucose meters are billed using the NC Medicaid Free BIN Meter program. BIN 610524, PCN 1016, Group 40026479, ID 066499643.***

Meters	Lancing Devices
ACCU-CHEK® Guide Retail care kit * (see above for billing)	ACCU-CHEK® Softclix lancing device kit (Black)
ACCU-CHEK® Guide Me Retail care kit * (see above for billing)	ACCU-CHEK® Fastclix lancing device kit
Test Strips	Control Solutions
ACCU-CHEK® AVIVA PLUS 50 ct test strips	ACCU-CHEK® Aviva glucose control solution (2 levels)
ACCU-CHEK® SMARTVIEW 50 ct test strips	ACCU-CHEK® SmartView glucose control solution (1 level)
ACCU-CHEK® Guide 50 ct test strips	ACCU-CHEK® Guide 2-Level control solution (2-levels)
ACCU-CHEK® Guide 100 ct test strips	
Lancets	
ACCU-CHEK® Softclix 100 ct Lancets	
ACCU-CHEK® Fastclix 102 ct Lancets	